EXHIBIT 10.24
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE OMISSIONS.
STRATEGIC COLLABORATION AND
LICENSE AGREEMENT
This Strategic Collaboration and License Agreement (the "Agreement")
is effective as of March 11, 2004 (the "Effective Date") between Isis
Pharmaceuticals, Inc., a Delaware corporation having an address at 0000 Xxxxxxx
Xxxxxx, Xxxxxxxx, XX 00000 ("Isis") and Alnylam Pharmaceuticals, Inc., a
Delaware corporation having an address at 000 Xxxxxxxx Xxxxx, Xxxxx 000,
Xxxxxxxxx, XX 00000 (together with its wholly owned subsidiaries Alnylam U.S.,
Inc., a Delaware corporation, and Alnylam Europe AG, a company organized under
the laws of Germany, "Alnylam"). Isis and Alnylam may be referred to herein as
the "Parties," or each individually as a "Party."
GUIDING PRINCIPLES
Isis is the leader in RNA-based drug discovery, has created
technology, intellectual property, expertise, facilities and resources to
discover and develop oligonucleotide drugs;
Alnylam is the leader in RNAi therapeutics, has developed and
acquired intellectual property, expertise and technology in RNAi therapeutics,
and is conducting research and drug discovery focused on Double Stranded RNA
drugs;
Isis and Alnylam desire to create a long-term strategic relationship
that will enhance the positions of both companies in RNA-based drug discovery;
Isis will continue to pursue RNA-based drug discovery technology very
broadly including all potential mechanisms of action. Isis will work with
Alnylam as Isis' primary means of participating in the potential value of Double
Stranded RNA Products, and will not enter into any collaborations with Third
Parties the primary purpose of which is to discover Double Stranded RNA
Products; and
Alnylam will focus on RNAi therapeutics and the use of Double
Stranded RNA.
The objectives of the strategic relationship are to:
- Enhance the leadership of Alnylam in RNAi therapeutics.
- Enhance the potential of Alnylam to develop Double Stranded RNA drugs.
- Defer Alnylam investments in Chemistry, Manufacturing and Controls (CMC).
- Enhance the patent positions of each Party with respect to Double Stranded
RNA drugs.
- Provide Isis with a means for participating in the success of RNAi
therapeutics.
ARTICLE 1
1
DEFINITIONS; EXHIBITS AND SCHEDULES
1.1 Capitalized terms used herein and not defined elsewhere herein have
the meanings set forth in Exhibit 1.1.
1.2 On or before March 19, 2004, the Parties shall both execute a mutually
satisfactory addendum transmittal instrument (the "Addendum Transmittal")
delivering all Exhibits and Schedules identified herein as attached to the
Addendum Transmittal.
ARTICLE 2
EQUITY INVESTMENT
2.1 Isis will purchase from Alnylam Pharmaceuticals, Inc., and Alnylam
Pharmaceuticals, Inc. will sell to Isis, 1,666,667 shares of Series D Preferred
Stock, at $6.00 per share (i.e., at an aggregate purchase price of $10,000,002),
on the terms contained in the Equity Documents.
ARTICLE 3
MANUFACTURING SERVICES RELATIONSHIP
3.1 At Alnylam's request, on the terms and conditions of the Manufacturing
Services Term Sheet attached hereto as Exhibit 3.1 attached to the Addendum
Transmittal, Isis and Alnylam will negotiate in good faith a manufacturing
services agreement (the "Manufacturing Services Agreement"), pursuant to which
Isis will provide Alnylam with manufacturing and related services relating to
Double Stranded RNA Products.
ARTICLE 4
COLLABORATIVE RESEARCH EFFORTS
4.1 Research Management Committee.
(A) To promote the success of the collaboration objectives and RNAi
technology, the Parties will establish a Research Management Committee ("RMC"),
which will be comprised of equal numbers of representatives of each of the
Parties and will meet at least twice per calendar year, alternating venues
between the vicinities of Cambridge, Massachusetts and Carlsbad, California, to
share scientific direction and data, to coordinate basic research experiments,
and to facilitate the guiding principles of the collaboration.
(B) Intellectual property representatives of each Party will be
invited to participate in RMC meetings and such meetings will provide a forum to
discuss patent prosecution and enforcement issues and to allocate responsibility
for the filing and prosecution of any Joint Patents.
(C) The Parties will use the RMC as a forum to update one another
regarding their respective Future Chemistry and Motif and Mechanism Patents.
2
(D) The RMC will establish a clearance policy that will govern any
publication or presentation by a Party in which such Party proposes to include
any previously undisclosed information or intellectual property Controlled by
the other Party.
(E) The RMC will continue in existence for three (3) years after the
Effective Date, subject to extension by mutual agreement of the Parties. Upon
termination of the RMC, the Parties will agree upon a strategy to make decisions
about the items in Sections 4.1 (b), (c), and (d).
ARTICLE 5
LICENSES GRANTED BY ISIS TO ALNYLAM
5.1 License Grants. Subject to the terms and conditions of this Agreement,
including, but not limited to, the restrictions set forth in Section 5.3, Isis
grants Alnylam the following licenses:
(A) Under Isis Current Motif and Mechanism Patents and Isis Current
Chemistry Patents, a license to research, develop, make, have made, use, import,
offer to sell and sell Double Stranded RNA and Double Stranded RNA Products.
(B) Subject to the terms of Section 11.8, under Isis Future Motif
and Mechanism Patents, Isis Future Chemistry Patents and Isis' rights in Joint
Patents, a license to research, develop, make, have made, use, import, offer to
sell and sell Double Stranded RNA and Double Stranded RNA Products.
(C) Under the Isis Current Motif and Mechanism Patents and Isis
Current Chemistry Patents, a license to research, develop, make, have made, use,
import, offer to sell and sell MicroRNA Products.
(D) Subject to the terms of Section 11.8, under the Isis Future
Motif and Mechanism Patents and Isis Future Chemistry Patents, a license to
research, develop, make, have made, use, import, offer to sell and sell MicroRNA
Products.
(E) A royalty-free, fully paid, license to practice any Know-How
disclosed to Alnylam during the performance of this Agreement, subject to the
non-disclosure but not the non-use provisions contained in Article 12.
(F) A fully paid, royalty-free nonexclusive license under Isis
Manufacturing Patents to research, develop, make, have made, use and import
Alnylam Products for Research Use.
5.2 License Exclusivity, Territory and Sublicenses.
3
(A) Subject to the terms and conditions of this Agreement, including
the restrictions set forth in Section 5.3, the licenses from Isis to Alnylam
granted in Sections 5.1(a) and (b) are worldwide and co-exclusive (with Isis),
with the exclusive right to grant Naked Sublicenses, and the licenses from Isis
to Alnylam granted in Sections 5.1 (c), (d), (e) and (f) are worldwide and
nonexclusive. Alnylam is not permitted to grant sublicenses under the licenses
granted in Sections 5.1(a) through 5.1(e), except that Alnylam is permitted to
grant (i) sublicenses in connection with a Bona Fide Drug Discovery
Collaboration, (ii) sublicenses in connection with a Development Collaboration,
(iii) Naked Sublicenses and (iv) sublicenses under the license granted in
Section 5.1(e) in connection with the discovery, development or
commercialization of any product. Alnylam is not permitted to grant sublicenses
under the licenses granted in Section 5.1(f).
(B) If Alnylam, on its own or through an Affiliate or collaborator
in a Bona Fide Drug Discovery Collaboration, has not reached the [**] stage of
development with any Alnylam Product by [**], the exclusive right to grant Naked
Sublicenses under the licenses granted in Sections 5.1(a) and 5.1(b) will
convert to a nonexclusive right.
(C) Alnylam cannot sublicense its right to grant Naked Sublicenses
under this Agreement except that Alnylam may permit its sublicensees to grant
further sublicenses in connection with an Alnylam Product.
(D) Notwithstanding the foregoing, Isis may (i) complete its pending
transaction with [**], provided that in such transaction Isis only grants to
[**] a nonexclusive license under Isis Current Motif and Mechanism Patents and
Isis Current Chemistry Patents for the manufacture and sale of chemically
modified oligonucleotides for research use only and (ii) continue to grant
licenses to Third Parties for the purpose of manufacturing and selling
oligonucleotides; provided that, to the extent such licenses cover Double
Stranded RNA, Isis will restrict such licenses to non-therapeutic uses.
5.3 Limitations on Licenses.
(A) The licenses granted under Section 5.1 above are not intended to
grant any rights to Alnylam to practice the Isis Excluded Technology. If Alnylam
wishes to license any Isis Excluded Technology for which Isis has the right to
grant a license or sublicense, Isis will negotiate in good faith an appropriate
license.
(B) Notwithstanding the licenses granted to Alnylam under Section
5.1, Isis retains its rights in the Isis Patent Rights and in the Joint Patents
(i) exclusively for the Isis Exclusive Targets and (ii) exclusively for the Isis
Encumbered Targets. Once a particular contractual restriction expires on an Isis
Encumbered Target, Alnylam's licenses under Section 5.1 will no longer be
limited under this Section 5.3(b) for such target and such target shall no
longer be an Isis Encumbered Target. Isis will update the [**] (as defined in
the letter agreement dated March 9, 2004 between Alnylam and Isis) provided to
Alnylam prior to the Effective Date and subsequent [**] provided to Alnylam
from time to time to remove targets that are no longer Isis Encumbered Targets
promptly upon receipt of a written request from Alnylam to update such [**],
but will not be required to update such [**] more frequently than once a
calendar quarter.
(C) Licenses to Isis Patent Rights that are joint patents with Third
Parties (i.e., invented by one or more Isis inventors and one or more non-Isis
inventors) are licensed subject to the retained rights of any non-Isis inventors
and their assignees and licensees. Any
4
such retained rights of non-Isis inventors and their assignees and licensees
existing as of the Effective Date are set forth in Exhibit 5.3(c) attached to
the Addendum Transmittal.
(D) Licenses to Isis Patent Rights that are subject to contractual
obligations between Isis and Third Parties in effect as of the Effective Date
are licensed subject to the restrictions and other terms described in Exhibit
5.3(d) attached to the Addendum Transmittal. Alnylam hereby agrees to comply,
and to cause its sublicensees to comply, with such restrictions and other terms.
5.4 Alnylam Covenant Regarding Sublicensing of Isis Patent Rights. Alnylam
shall use good faith efforts to include sublicenses under the licenses under the
Isis Patent Rights granted to Alnylam in Sections 5.1(a) and 5.1(b) in any Third
Party collaboration or license agreement in which Alnylam grants rights to
develop and commercialize Double Stranded RNA Products, unless the technology
covered by such licensed Isis Patent Rights would not reasonably be expected to
advance the goals of such Third Party collaboration or license relationship.
ARTICLE 6
LICENSES GRANTED BY ALNYLAM TO ISIS
6.1 License Grants. Subject to the terms and conditions of this Agreement,
including, but not limited to, the restrictions set forth in Section 6.5,
Alnylam grants Isis the following licenses:
(A) A fully-paid, royalty-free, nonexclusive license under Alnylam
Current Motif and Mechanism Patents and Alnylam Current Chemistry Patents to
research, develop, make, have made, use and import Isis Products for Research
Use.
(B) Subject to the terms of Section 11.8, a fully paid, royalty-free
nonexclusive license under Alnylam Future Motif and Mechanism Patents and
Alnylam Future Chemistry Patents to research, develop, make, have made, use and
import Isis Products for Research Use.
(C) A nonexclusive license under Alnylam Current Motif and Mechanism
Patents and Alnylam Current Chemistry Patents to research, develop, make, have
made, use, import, offer to sell and sell Isis Single Stranded Products
(D) Subject to the terms of Section 11.8, a nonexclusive license
under Alnylam Future Motif and Mechanism Patents and Alnylam Future Chemistry
Patents to research, develop, make, have made, use, import, offer to sell and
sell Isis Single Stranded Products.
(E) Under the Alnylam Current Motif and Mechanism Patents and
Alnylam Current Chemistry Patents, a nonexclusive license to research, develop,
make, have made, use, import, offer to sell and sell MicroRNA Products.
5
(F) Subject to the terms of Section 11.8, under the Alnylam Future
Motif and Mechanism Patents and Alnylam Future Chemistry Patents, a nonexclusive
license to research, develop, make, have made, use, import, offer to sell and
sell MicroRNA Products.
(G) A worldwide, royalty-free, fully paid, nonexclusive license to
practice any Know-How disclosed to Isis during the performance of this
Agreement, subject to the non-disclosure but not the non-use provisions
contained in Article 12.
6.2 License Option. For each Gene Target in the Isis Target Pool (as
further described below) Alnylam grants Isis an exclusive option to obtain (on a
Reserved Target-by-Reserved Target basis), subject to the terms and conditions
of this Agreement, including, but not limited to, the restrictions set forth in
Section 6.5, a license under (i) Alnylam Current Motif and Mechanism Patents and
Alnylam Current Chemistry Patents and (ii) subject to the terms of Section 11.8,
Alnylam Future Motif and Mechanism Patents, Alnylam Future Chemistry Patents and
Alnylam's rights in Joint Patents, to research, develop, make, have made, use,
import, offer for sale and sell Double Stranded RNA and Double Stranded RNA
Products.
(A) This license, when the option is exercised, will be exclusive
with respect to Isis Exclusive Targets and co-exclusive (with Alnylam) with
respect to Isis Co-Exclusive Targets.
(B) This option will expire on a Reserved Target-by-Reserved Target
basis if Isis has not paid Alnylam the option fee set forth in Section 8.1 below
before the earlier of (i) [**] with respect to such Reserved Target, (ii) the
[**] anniversary of the date such Reserved Target [**] or the [**] anniversary
of the date such Reserved Target [**] and Isis is [**] or (iii) the date [**]
with respect to such Reserved Target.
(C) For any Reserved Target for which Isis obtains a license from
Alnylam under this Section 6.2, Isis will use Commercially Reasonable Efforts
(either on its own or in an Antisense Drug Discovery Program or Development
Collaboration) to develop and commercialize Double Stranded RNA Products that
modulate such Reserved Target.
6.3 Sublicenses.
(A) With respect to any license granted by Alnylam pursuant to
Section 6.1(a), 6.1(b) or 6.2, Isis may only grant a sublicense to a Third Party
solely for the purpose of enabling such Third Party to collaborate with Isis in
an Antisense Drug Discovery Program or to develop and commercialize an Isis
Product in a Development Collaboration. With respect to any license granted by
Alnylam pursuant to Section 6.1(c), 6.1(d), 6.1(e), 6.1(f) or 6.1(g), Isis may
grant a sublicense to a Third Party in connection with the discovery,
development or commercialization of any product.
(B) Notwithstanding anything in this Agreement to the contrary, Isis
may not enter into any drug discovery collaboration the primary purpose of which
is to discover Double Stranded RNA Products and/or to develop Double Stranded
RNA Products to any point up to the [**].
6.4 Target Pool.
6
(A) Reserved Target Slots. Initially, Isis will have a pool (the
"Isis Target Pool") containing up to [**] slots for which Isis can designate
certain Gene Targets solely for Antisense Drug Discovery Programs (each such
slot, a "Target Slot" and any Gene Target occupying such a slot, a "Reserved
Target"); provided, however, that on January 1 of each year starting with
January 1, [**], Isis will gain the right to purchase one additional Target Slot
by paying Alnylam [**] per each additional Target Slot, which additional Target
Slot shall be a Co-Exclusive Target Slot except as otherwise provided in Section
6.4(f). These rights are cumulative and, subject to Section 17.2(c) do not
expire during the License Term. Furthermore, in the event that Isis pays the
$[**] license option fee for a Reserved Target pursuant to section 8.1, such
Reserved Target will be considered to have graduated from the Isis Target Pool,
and, subject to Section 6.4(e), Isis will be permitted to designate a new
Reserved Target to fill the open Target Slot in the Isis Target Pool.
(B) Initial Designations; Conversion of Target Slots. Initially,
subject to Section 6.4(e), Isis can designate up to [**] Reserved Targets as
Isis Exclusive Targets (the "Isis Exclusive Targets", and each Target Slot
occupied by an Isis Exclusive Target, an "Exclusive Target Slot") and up to [**]
Reserved Targets as Isis Co-Exclusive Targets (the "Isis Co-Exclusive Targets",
and each Target Slot occupied by an Isis Co-Exclusive Target, a "Co-Exclusive
Target Slot"). On January 1 of each year starting with January 1, [**], one of
the [**] initial Co-Exclusive Target Slots will convert into an Exclusive Target
Slot such that the initial [**] Target Slots will all be Exclusive Target Slots
by January 1, [**]. Subject to section 6.4(f), the Isis Co-Exclusive Target in a
Co-Exclusive Target Slot that converts to an Exclusive Target Slot will become
an Isis Exclusive Target.
(C) Removing/Adding/Redesignating Targets. After the Effective Date
and no more than [**] period (a "Target Reallocation Period"), Isis may do any
of the following:
(i) Remove a Gene Target from the Isis Target Pool (which,
following such removal will create an open Target Slot);
(ii) Add a new Gene Target to any open Target Slot (subject to
the procedures and provisions of Section 6.4(e); or
(iii) Redesignate an Isis Co-Exclusive Target as an Isis
Exclusive Target, provided that (A) an open Exclusive Target
Slot is available, which may be made available by Isis's
simultaneous redesignation of an Isis Exclusive Target as an
Isis Co-Exclusive Target, and (B) Alnylam does not have an
Active Program with respect to such Isis Co-Exclusive Target
or has not entered into a Bona Fide Drug Discovery
Collaboration or Development Collaboration that prevents
Alnylam from granting Isis an exclusive license with respect
to such Isis Co-Exclusive Target.
Notwithstanding the foregoing provisions of this Section 6.4(c), in
any Target Reallocation Period, Isis cannot remove or redesignate, or any
combination thereof, a number of Reserved Targets that exceeds the number
calculated by dividing the then current number of Target Slots by [**]and
rounding down to the nearest whole number. For the purpose of the limitation
described in the immediately preceding sentence, (x) removing a Gene Target from
the Isis Target Pool and then filling the open Target Slot created by such
removal shall
7
count as a single removal and (y) redesignating an Isis Co-Exclusive Target as
an Isis Exclusive Target and simultaneously redesignating an Isis Exclusive
Target as an Isis Co-Exclusive Target in order to make available an open
Exclusive Target Slot to permit the former redesignation shall count as a single
redesignation. Once Isis removes a Gene Target from the Isis Target Pool, Isis
will be prevented from later adding such Gene Target to the Isis Target Pool
until [**] have passed from the date Isis removed such Gene Target.
(D) New Target Request. When Isis wishes to add a new Gene Target to
occupy a vacant Target Slot, it will provide Alnylam with written notice (the
"Request Notice") of the Gene Target it wishes to add (the "Proposed Reserved
Target"). The Request Notice will include the gene name, the NCBI accession
number or nucleic acid sequence for the Proposed Reserved Target and whether
Isis wants the Proposed Reserved Target, if accepted, to be an Isis Exclusive
Target or an Isis Co-Exclusive Target.
(E) New Target Rejection/Approval. Within [**] of receipt of the
Request Notice, Alnylam will give Isis written notice if any of the criteria set
forth below applied to such Proposed Reserved Target at the time of Alnylam's
receipt of the Request Notice. If, at such time, the Proposed Reserved Target is
(i) subject to Alnylam's own Active Program [**], (ii) encumbered by a
contractual obligation between Alnylam and a Third Party that would preclude
Alnylam from granting a license under Section 6.2 with respect to the Proposed
Reserved Target or (iii) the subject of Alnylam's good faith negotiations to
enter into a contractual obligation within the [**] following receipt of the
Request Notice with a Third Party (as supported by a written request from such
Third Party) that would preclude Alnylam from granting a license under Section
6.2 with respect to the Proposed Reserved Target, then the Proposed Reserved
Target will be rejected and will not become a Reserved Target. If the Proposed
Reserved Target is not rejected under this subsection (e), the Proposed Reserved
Target will become an Isis Co-Exclusive Target or an Isis Exclusive Target (as
set forth in the Request Notice). If Alnylam can only grant a license to a
Proposed Reserved Target on a co-exclusive basis, it will notify Isis in
writing. Isis will then have the option to accept the Proposed Reserved Target
as one of its Isis Co-Exclusive Targets. Alnylam will promptly notify Isis in
writing if a rejected Proposed Reserved Target later becomes available to be
designated as a Reserved Target or if an Isis Co-Exclusive Target later becomes
available to be designated as an Isis Exclusive Target.
(F) Target Redesignation Procedures. In each year that a
Co-Exclusive Target Slot converts to an Exclusive Target Slot pursuant to
section 6.4(b), Isis will provide Alnylam with written notice designating which
Isis Co-Exclusive Target (the "Proposed Redesignated Target") it wishes to
become an Isis Exclusive Target occupying the new Exclusive Target Slot. Alnylam
will have [**] after the receipt of such notice either to confirm that the
Proposed Redesignated Target has become an Isis Exclusive Target or to disallow
such redesignation. Alnylam may only disallow such redesignation if, at the time
of Alnylam's receipt of Isis' notice regarding the Proposed Redesignated Target,
Alnylam has an Active Program with respect to such Proposed Redesignated Target
or has entered into a contractual obligation with a Third Party that prevents
Alnylam from granting Isis an exclusive license with respect to such Proposed
Redesignated Target. In the event that Alnylam disallows the redesignation of a
Proposed Redesignated Target, Isis will use the same procedure to designate
another Isis Co-Exclusive Target as a Proposed Redesignated Target, and Alnylam
will follow the same procedure to confirm or disallow the redesignation
8
of such Proposed Redesignated Target as an Isis Exclusive Target. In the event
that Isis has proposed all of the then-existing Isis Co-Exclusive Targets as the
Proposed Redesignated Target and Alnylam has disallowed each such proposal, then
(i) if the calendar year is [**], Isis will have the right to purchase an
additional [**] Target Slot in [**], or (ii) if the calendar year is [**] Isis'
right to purchase a [**] Target Slot in pursuant to section 6.4(a) will become a
right to purchase an Exclusive Target Slot in such year, or (iii) if the
calendar year is [**] or later, Isis's right to purchase a [**] pursuant to
section 6.4(a) will become a right to purchase a [**], provided, however, that
in no event shall the number of Exclusive Target Slots held by Isis exceed [**].
(G) Diligence on Rejected Targets. If (i) Alnylam rejects a Proposed
Reserved Target under Section 6.4(e) above and (ii) Alnylam has [**] with
respect to such rejected Proposed Reserve Target by the [**] anniversary of the
date Alnylam rejected such Proposed Reserved Target if Alnylam is working on
such target alone, or the [**] anniversary of the date Alnylam rejected such
Proposed Reserved Target if such rejected Proposed Reserved Target is subject to
a contractual obligation between Alnylam and a Third Party that would preclude
Alnylam from granting a license under Section 6.2 with respect to the rejected
Proposed Reserved Target but Alnylam is [**], then [**] such rejected Proposed
Reserved Target [**].
(H) Diligence Obligations in Third Party Contractual Obligations.
With the goal of minimizing contractual encumbrances on Alnylam Patent Rights
with respect to Gene Targets in the absence of a reasonable intent to discover
and develop products that modulate such Gene Targets by Third Parties with which
Alnylam enters into such contractual obligations, Alnylam intends to seek
reasonable diligence obligations from Third Parties in negotiating contracts
between Alnylam and such Third Parties that would constitute contractual
obligations of Alnylam that would preclude Alnylam from granting licenses to
Isis under Section 6.2 with respect to Proposed Reserved Targets or that would
prevent Alnylam from granting Isis exclusive licenses with respect to Proposed
Redesignated Targets; provided that Isis hereby acknowledges that such diligence
obligations are often heavily negotiated in biotechnology license and
collaboration agreements and that this Section 6.4(h) shall not prevent Alnylam
from entering into contracts between Alnylam and Third Parties in accordance
with Alnylam's reasonable business judgment.
(I) Confidentiality. The fact that Isis has designated or removed a
particular Gene Target within the Isis Target Pool is Confidential Information
of Isis, or that Alnylam has rejected a particular Gene Target proposed for a
Target Slot or disallowed the redesignation of a particular Gene Target is
Confidential Information of Alnylam, subject to the provisions of Article 12.
Neither Party shall disclose such Confidential Information of the other Party to
any Third Party, including its Third Party collaborators, or use such
Confidential Information of the other Party to guide its own (or its Third Party
collaborators') decisions to pursue particular Gene Targets, but Alnylam can use
such Confidential Information of Isis to decline a Third Party's request for a
license to such Gene Target.
6.5 Limitations on Licenses.
(A) The licenses granted under Sections 6.1 and 6.2 above are not
intended to grant any rights to Isis to practice the Alnylam Excluded
Technology. If Isis wishes to license any Alnylam Excluded Technology for which
Alnylam has the right to grant a sublicense, Alnylam will negotiate in good
faith an appropriate license.
(B) Licenses to Alnylam Patent Rights that are joint patents with
Third Parties (i.e., invented by one or more Alnylam inventors and one or more
non-Alnylam inventors)
9
are licensed subject to the retained rights of any non-Alnylam inventors and
their assignees and licensees. There are no Alnylam Current Chemistry Patents or
Alnylam Current Motif and Mechanism Patents subject to such retained rights.
(C) Licenses to Alnylam Patent Rights that are subject to
contractual obligations between Alnylam and Third Parties in effect as of the
Effective Date are licensed subject to the restrictions and other terms
described in Exhibit 6.5(c) attached to the Addendum Transmittal. Isis hereby
agrees to comply, and to cause its sublicensees to comply, with such
restrictions and other terms.
(D) Notwithstanding anything to the contrary herein, the licenses to
Alnylam Patent Rights hereunder initially shall not include licenses to Patents
licensed by Alnylam from Stanford University under any agreement between Alnylam
and Stanford University in effect as of the Effective Date; provided that if any
such licensed Patents become issued Patents, Isis shall have the option of
expanding its licenses to Alnylam Patent Rights hereunder to include such issued
Patents by notifying Alnylam of such election and agreeing to pay to Alnylam, in
addition to all amounts otherwise payable to Alnylam hereunder (and without any
right under Section 8.2 to reduce such otherwise payable amounts as a
consequence of such additional payment amounts), all amounts that (i) become
payable by Alnylam to Stanford University as a result of such expansion of Isis'
licenses and Isis' (and its Affiliates' and sublicensees') exercise of its
rights thereunder and (ii) are described on Exhibit 6.5(d) attached hereto.
ARTICLE 7
LICENSE FEES AND ROYALTIES PAYABLE TO ISIS
7.1 License Fees. Alnylam will pay an initial, irrevocable, noncreditable
and non-refundable license fee of $5,000,000 to Isis, $3,000,000 of which will
be due within 5 business days of the Effective Date and the remaining $2,000,000
of which will be due on January 3, 2005.
7.2 Royalties. Subject to the terms and conditions of, and during the term
of, this Agreement, Alnylam will pay to Isis royalties on sales of Alnylam
Products by Alnylam, its Affiliates or sublicensees (except Naked Sublicensees)
equal to [**]% of Net Sales. Alnylam may reduce the royalty due under this
section by [**]% of any additional royalties that Alnylam owes to Third Parties
on such Alnylam Product that arise from Alnylam acquiring access to new
technologies after the Effective Date; provided, however that (a) the royalty
due under this section can never be less than a floor of [**]% and (b)
additional royalties arising as the result of the addition, pursuant to Section
11.8, of Isis Future Chemistry Patents or Isis Future Motif and Mechanism
Patents to the Isis Patent Rights licensed to Alnylam cannot be used to reduce
the royalty.
7.3 Development Milestones.
(A) Alnylam, its Affiliates or sublicensees (except Naked
Sublicensees) will pay to Isis the following milestone payments for each Alnylam
Product within [**] after the first achievement of each of the following events:
10
MILESTONE EVENT MILESTONE PAYMENT
--------------- -----------------
Initiation of Phase I Trial US$[**]
Initiation of Phase III Trial US$[**]
Filing IND US$[**]
Marketing Approval US$[**]
Each milestone payment under this Section 7.3(a) will only be due on [**]
Alnylam Product that modulates a particular Gene Target to trigger such
milestone payment, whether such milestone is achieved by Alnylam or an Affiliate
or sublicensee of Alnylam.
(B) Alnylam, its Affiliates or sublicensees will pay to Isis a
milestone payment of US$[**] for the [**] MicroRNA Product that is an Alnylam
Product that modulates a particular Gene Target within [**] after such MicroRNA
Product reaches the initiation of [**], and not for any other MicroRNA Product
that is an Alnylam Product that modulates the particular Gene Target.
7.4 Sublicensing Revenue on Naked Sublicenses. Alnylam will pay Isis [**]%
of Sublicense Revenue from Naked Sublicenses granted by Alnylam and its
Affiliates under this Agreement.
7.5 Technology Access Fees from Bona Fide Collaborations.
(A) Alnylam will pay Isis a percentage of Technology Access Fees
received by Alnylam and its Affiliates pursuant to Bona Fide Drug Discovery
Collaborations and Development Collaborations entered into between Alnylam and a
Third Party. Such percentage will be calculated based on the year in which
Alnylam executes such Bona Fide Drug Discovery Collaboration or Development
Collaboration agreement using the following table:
YEAR 2004/2005 2006 2007 2008+
---- --------- ---- ---- -----
APPLICABLE PERCENTAGE [**]% [**]% [**]% [**]%
(B) Notwithstanding the foregoing, for any Bona Fide Drug Discovery
Collaboration or Development Collaboration agreement, Alnylam will pay Isis a
minimum fee, payable upon the first Alnylam Product developed pursuant to such
Bona Fide Drug Discovery Collaboration agreement reaching [**] or within [**]
after the execution of such Development Collaboration agreement, equal to the
lesser of (i) $[**] or (ii) [**]% of the Technology Access Fees from such
collaboration; provided, however that Alnylam may credit any amounts paid Isis
pursuant to Section 7.5(a) above as the result of the same Bona Fide Drug
Discovery Collaboration or Development Collaboration agreement against this
minimum fee with such amounts credited only once, and provided further that if
following such payment, additional Technology Access Fees are owed to Isis for
such Bona Fide Drug Discovery Collaboration or Development Collaboration, the
amounts paid under this Section 7.5(b) (after crediting of any previous
Technology Access Fees paid under Section 7.5(a) in accordance with the
immediately preceding proviso) will be creditable against such future Technology
Access Fees. In addition, for each of (i) the Research Collaboration and License
Agreement between Merck and Co. and Alnylam dated September 8, 2003, as amended
through the Effective Date (the "Merck Agreement") and (ii) the Bona Fide Drug
Discovery Collaboration agreement currently being negotiated by Alnylam (the
"Pending Agreement"), if such agreement is executed within [**] the Effective
Date, [**] any Technology Access Fees [**] a fee of $1,000,000 for the [**]
Alnylam Product for a particular Gene Target from each such agreement that
reaches [**]; provided, however, that if Alnylam and Merck or Alnylam and the
potential new collaboration partner [**] Agreement or the Pending Agreement
after the Effective Date, then such [**] Agreement or Pending Agreement [**]
subject to all the terms and conditions of this Agreement, including but not
limited to the terms of this Section 7.5; provided further, however, that if the
inclusion by Alnylam of a sublicense under Isis Patent Rights licensed to
Alnylam in this Agreement plays a material role in increasing [**] Alnylam
pursuant to the Pending [**] Agreement, any such increase [**] shall be
considered to be Technology Access Fees subject to the provisions of section
7.5(a).
11
ARTICLE 8
LICENSE FEES AND ROYALTIES PAYABLE TO ALNYLAM
8.1 Option Fee. For each Isis Reserved Target for which Isis exercises its
option granted pursuant to Section 6.2, Isis will pay Alnylam an irrevocable,
noncreditable and non-refundable option fee of $[**] due upon the date of
exercise. Isis may credit any $[**] payment made under Section 6.4(a) for the
Target Slot occupied by such Reserved Target against this option fee. The option
fee is only payable once per Gene Target.
8.2 Royalties. Subject to the terms and conditions of, and during the term
of, this Agreement, Isis will pay to Alnylam royalties on sales of Isis Products
by Isis, its Affiliates or sublicensees equal to [**]% of Net Sales. Isis may
reduce the royalty due under this section by [**]% of any additional royalties
that Isis owes to Third Parties on such Isis Product that arise from Isis
acquiring access to new technologies after the Effective Date; provided, however
that that (a) the royalty due under this section can never be less than a floor
of [**]%, (b) additional royalties arising as the result of the addition,
pursuant Section 11.8, of Alnylam Future Chemistry Patents or Alnylam Future
Motif and Mechanism Patents to the Alnylam Patent Rights licensed to Isis, or as
the result of an expansion of Isis' licenses pursuant to Section 6.5(d), cannot
be used to reduce the royalty and (c) Isis shall not be entitled to reduce,
pursuant to this sentence, its royalty obligation to Alnylam below a royalty
obligation equal to the lesser of (i) Alnylam's aggregate royalty obligations
[**] existing as of the Effective Date [**] and (ii) Alnylam's aggregate royalty
obligations [**] as such obligations may be reduced from time to time after the
Effective Date.
8.3 Development Milestones.
(A) Isis, its Affiliates or sublicensees will pay to Alnylam the
following milestone payments for each Isis Product within [**] after the first
achievement of each of the following events:
MILESTONE EVENT MILESTONE PAYMENT
--------------- -----------------
Initiation of Phase I Trial US$[**]
Initiation of Phase II Trial US$[**]
Filing NDA US$[**]
Marketing Approval US$[**]
Each milestone payment under this Section 8.3(a) will only be due on [**] Isis
Product that modulates a particular Gene Target to trigger such milestone
payment, whether such milestone is achieved by Isis or an Affiliate or
sublicensee of Isis.
(B) Isis, its Affiliates or sublicensees will pay to Alnylam a
milestone payment of US$[**] for the [**] Isis Single Stranded Product that is
an Isis Product that modulates a particular Gene Target within [**] after such
Isis Single Stranded Product reaches the initiation of IND-Enabling Studies and
not for any other Isis Single Stranded Product that modulates the particular
Gene Target.
12
(C) Isis, its Affiliates or sublicensees will pay to Alnylam a
milestone payment of US$[**] for the [**] MicroRNA Product that is an Isis
Product that modulates a particular Gene Target within [**] after such MicroRNA
product reaches the initiation of [**], and not for any other MicroRNA Product
that is an Isis Product that modulates the particular Gene Target.
ARTICLE 9
OTHER PAYMENT TERMS
9.1 Payments. All payments by a Party under this Agreement will be made in
United States dollars by bank wire transfer in next day available funds to such
bank account in the United States designated in writing by Alnylam or Isis, from
time to time. Royalties payable under Sections 7.2 and 8.2 shall be payable on a
quarterly basis within 45 days after the end of each calendar quarter. The Party
with such royalty obligation (the "Royalty-Paying Party") shall provide the
other Party with a report setting forth (i) gross sales of Alnylam Products or
Isis Products, as applicable, by the Royalty-Paying Party, its Affiliates and
sublicensees, (ii) all deductions from such gross sales taken in calculating Net
Sales, (iii) Net Sales of Alnylam Products or Isis Products, as applicable, by
the Royalty-Paying Party, its Affiliates and sublicensees, (iv) royalties
payable based on such Net Sales and (v) all other information relevant to the
calculation of such royalties, on a product-by-product and country-by-country
basis, for each calendar quarter within [**] after the end of such calendar
quarter.
9.2 Late Payments; Collections. In the event that any payment, including
royalty, milestone, Sublicense Revenue or Technology Access Fee payments, due
hereunder is not made when due, the payment will bear interest from the date due
at the lesser of (i) 1.5% per month, compounded monthly, or (ii) the highest
rate permitted by law; provided, however, that in no event will such rate exceed
the maximum legal annual interest rate. If a Party disputes in writing the
amount of an invoice presented by the other Party within [**] of receipt of such
invoice, interest will only be due on the correct amount as later determined or
agreed. The payment of such interest will not limit a Party from exercising any
other rights it may have as a consequence of the lateness of any payment. In
addition, each Party agrees to pay all external costs of collection, including
reasonable attorneys' fees, incurred by the other Party in enforcing the payment
obligations after a due date has passed under this Agreement.
9.3 Audit Rights.
(A) Upon the written request of Isis or Alnylam, as the case may be,
and not more than once in each calendar year, Isis or Alnylam will permit the
other Party's independent certified public accountant to have access upon
reasonable advance notice and during normal business hours to its records as may
be reasonably necessary to verify the accuracy of the royalty reports hereunder
for the current year and the preceding 2 years prior to the date of such
request. The accounting firm will disclose to the auditing Party only whether
the royalty reports are correct or incorrect, the specific details concerning
any discrepancies, and the corrected amount of Net Sales and royalty payments.
No other information will be provided to the auditing Party. Once a Party has
audited a particular calendar year under this section, the Party will be
precluded from subsequently auditing such calendar year. In any sublicense
granted by a Party under this Agreement, such Party will
13
endeavor to secure a similar audit right and if reasonably requested by the
other Party will enforce such audit right.
(B) If such accounting firm concludes that additional royalties were
owed during such period, the delinquent Party will pay the additional royalties
within 90 days of the date such Party receives the accounting firm's written
report. The fees charged by such accounting firm will be paid by the auditing
Party unless the additional royalties, milestones or other payments owed by the
audited Party exceed 5% of the royalties, milestones or other payments paid for
the time period subject to the audit, in which case the audited Party will pay
the reasonable fees and expenses charged by the accounting firm.
(C) Each Party will treat all financial information subject to
review under this Section 9.3 or under any sublicense agreement in accordance
with the confidentiality provisions of Article 12, and will cause its accounting
firm to enter into an acceptable confidentiality agreement obligating such firm
to retain all such financial information in confidence pursuant to such
confidentiality agreement.
9.4 Taxes. If laws, rules or regulations require withholding of income
taxes or other taxes imposed upon payments set forth in Article 7 or 8, each
Party will make such withholding payments as required and subtract such
withholding payments from the payments set forth in Article 7 or 8. Each Party
will submit appropriate proof of payment of the withholding taxes to the other
Party within a reasonable period of time. The Parties will cooperate to obtain
the appropriate tax clearance and/or recover any such withholdings if possible.
ARTICLE 10
ALNYLAM RIGHT OF FIRST NEGOTIATION; PREFERRED LICENSEE
10.1 Right of First Negotiation. Isis will notify Alnylam in writing once
(i) Isis, on its own with no subsequent rights to Third Parties, intends to
initiate [**]or (ii) if a Third Party with which Isis has a Development
Collaboration or a collaboration on [**] before or during clinical development
or commercialization with no subsequent rights to Third Parties. Alnylam will
have [**] from the receipt of such notice to notify Isis in writing whether or
not Alnylam wishes to negotiate with Isis regarding the development and/or
commercialization of such Isis Product. If Alnylam fails to respond to Isis'
notice within the [**] or if Alnylam declines in writing to exercise its right
of first negotiation, then Isis will be free to develop and commercialize
(either on its own or with a Third Party) the Isis Product. If Alnylam wishes to
negotiate a license or development or commercialization rights in such Isis
Product, the Parties will negotiate in good faith the terms of the license or
collaboration agreement. If, despite good faith negotiations, Alnylam and Isis
do not reach agreement within [**] from Alnylam's exercise of its right of first
negotiation, then Isis will be free to develop and commercialize (either on its
own or with a Third Party) the Isis Product; provided that during the period
prior to the latest of (x) the initiation of [**] the Isis Product, (y) the [**]
anniversary of the commencement of [**] for the Isis Product or (z) in the case
of an Isis Product [**] after the commencement of [**], Isis shall not enter
into a license or collaboration agreement with a Third Party for such Isis
Product on terms (the "More Favorable Terms") that are in the aggregate
materially more favorable to the Third Party than
14
the terms on which Isis most recently offered in writing to grant such rights to
Alnylam without first offering the More Favorable Terms to Alnylam.
10.2 Preferred Licensee. If, after the Effective Date, Alnylam grants to
any Third Party that is not a Major Pharmaceutical Company a license under the
Alnylam Patent Rights to develop and commercialize Double Stranded RNA Products,
then if (a) either (i) the [**] terms of such license are more favorable to the
Third Party than the [**] terms hereunder with respect to Isis Products are to
Isis or (ii) the [**] covered by such license exceeds the [**] potentially
licensed to Isis hereunder for development and commercialization of Double
Stranded RNA Products, and (b) the roles to be played by Alnylam and such Third
Party in the development and commercialization of Double-Stranded RNA Products
under such Third Party license, the nature of the Gene Targets covered by such
Third Party license and any other relevant terms of such Third Party license do
not collectively justify the conditions described in the preceding clauses
(a)(i) and/or (a)(ii), then Alnylam shall modify the terms of its licenses to
Isis hereunder with respect to such conditions so that they are reasonably
equivalent to those granted to the Third Party.
ARTICLE 11
INTELLECTUAL PROPERTY
11.1 Ownership of Inventions.
(A) Each Party will solely own all inventions, technology,
discoveries, or other proprietary property (collectively, "Inventions") that are
made (as determined by U.S. rules of inventorship) solely by employees of or
consultants to that Party under this Agreement.
(B) Isis and Alnylam will jointly hold title to all Inventions,
whether or not patentable, that are made (as determined by the U.S. rules of
inventorship) jointly by employees of or consultants to Isis and Alnylam, as
well as to Patents filed thereon. Such Inventions will be "Joint Inventions,"
and Patents claiming such Joint Inventions will be "Joint Patents." Isis and
Alnylam will promptly provide each other with notice whenever a Joint Invention
is made. The Parties agree and acknowledge that, except insofar as this
Agreement provides otherwise, the default rights conferred on joint owners under
US patent law, including the right of each Party to independently practice,
license and use a Joint Patent, will apply in relation to the Joint Patents
throughout the world as though US patent law applied worldwide.
(C) The Parties agree, upon reasonable request, to execute any
documents reasonably necessary to effect and perfect each other's ownership of
any Invention.
11.2 Filing and Prosecution of Isis and Alnylam Patent Rights.
(A) Isis and Alnylam will work closely, through their interactions
on the RMC to ensure that, to the greatest degree permitted by United States and
foreign patent laws, Patents for inventions relating to all aspects of Double
Stranded RNA are obtained and shared.
15
(B) Isis will be responsible for preparing, filing, prosecuting,
maintaining and taking such other actions as are reasonably necessary or
appropriate with respect to the Isis Patent Rights.
(C) Alnylam will be responsible for preparing, filing, prosecuting,
maintaining and taking such other actions as are reasonably necessary or
appropriate with respect to the Alnylam Patent Rights.
(D) Each Party will endeavor in good faith to coordinate its efforts
with those of the other Party to minimize or avoid interference with the
prosecution of the other Party's Patents. Neither Party will initiate or
participate in any opposition, reexamination, interference, litigation or other
proceeding for the purpose of narrowing or invalidating any claim in a Patent of
the other Party. Promptly after the Effective Date, Isis shall discontinue its
participation in the opposition proceeding relating to the following Patent
Controlled by Alnylam: EP 1,144,623 (Inventors: X. Xxxxxxxx and X. Xxxxxx).
(E) At either Party's request, the other Party will keep the
requesting Party continuously informed of and provide documentation of all
significant matters relating to the preparation, filing, prosecution and
maintenance of any designated Patent.
11.3 Filing and Prosecution of Jointly Owned Patents.
(A) The Research Management Committee will designate one of the
Parties as being the responsible Party for preparing, filing, prosecuting,
maintaining and taking such other actions as are reasonably necessary or
appropriate with respect to any Joint Patent.
(B) Each Party will keep the other Party continuously informed of
all significant matters relating to the preparation, filing, prosecution and
maintenance of Joint Patents, and shall provide the other Party with copies of
any substantial prosecution papers within thirty days of receipt.
11.4 Costs and Expenses.
(A) Each Party will bear its own costs and expenses in filing,
prosecuting, maintaining and extending the Alnylam Patent Rights and Isis Patent
Rights, respectively.
(B) The Parties will pay equal shares of all costs and expenses in
filing, prosecuting, maintaining and extending the Joint Patents.
11.5 Enforcement.
(A) Each Party will promptly advise the other of any suspected or
actual infringement of the Isis Patent Rights, Alnylam Patent Rights, or Joint
Patents by any person that reasonably affects the other Party's business. The
notice shall set forth the facts of such infringement or misappropriation in
reasonable detail.
(B) Subject to subsections (c) and (h) below, Alnylam will have the
sole and exclusive right, in its sole discretion and at its expense, to assert
and enforce any Isis Patent Rights, Alnylam Patent Rights or Joint Patents
against any party engaging in an unlicensed or
16
unauthorized making, having made, using, selling, offering for sale or importing
of any allegedly infringing Double Stranded RNA.
(C) For any enforcement by Alnylam under subsection (b) above that
includes Isis Patent Rights covering a [**] chemical modification, Isis will
actively participate in the planning and conduct of such enforcement and will
take the lead of such enforcement to the extent that the scope or validity of
any such Isis Patent Rights covering a [**] chemical modification is at risk.
(D) Except as set forth in Sections 11.5(b) and (h),
(I) Isis will have the sole and exclusive right, in its sole
discretion and at its expense, to assert and enforce any Isis Patent Rights;
(II) Alnylam will have the sole and exclusive right, in its
sole discretion and at its expense, to assert and enforce any Alnylam Patent
Rights; and
(III) The RMC will agree in advance on the enforcement of any
Joint Patent and will apportion enforcement responsibilities and recoveries
amongst the parties.
(E) The rights granted hereunder to Alnylam to enforce certain
licensed in or jointly owned Isis Patent Rights are further limited as described
in Exhibit 5.3(d) attached to the Addendum Transmittal. The rights granted
hereunder to Isis to enforce certain licensed in or jointly owned Alnylam Patent
Rights are further limited as described in Exhibit 6.5(c) attached to the
Addendum Transmittal.
(F) The nonenforcing Party will have the right, at its own expense,
to participate in the conduct of the enforcement action and to be represented in
such action by its own counsel.
(G) The enforcing Party will not enter into any settlement that
impacts the scope or interpretation of any claim of any Joint Patent or of any
Patent of the nonenforcing Party without prior written authorization of the
nonenforcing Party.
(H) If the Party with enforcement rights under section (b) or (d)
above (the "Enforcing Party") fails to initiate proceedings against any actual
or suspected infringement within [**] of receipt of written request for
enforcement from the other Party (the "Nonenforcing Party") and if the infringer
is directly competing with a Product (the "Affected Product") of such
Nonenforcing Party, then (i) if the license granted in this Agreement under
which the Nonenforcing Party is selling the Affected Product is exclusive or
co-exclusive, the Nonenforcing Party will have the right to assert and enforce
the patents that are allegedly being infringed, or (ii) if the license granted
in this Agreement under which the Nonenforcing Party is selling the Affected
Product is non-exclusive, the Nonenforcing Party will have obligation to pay
royalties during the period for which the Enforcing Party fails to initiate
proceedings or take other action (including without limitation entering into a
licensing arrangement) to eliminate such infringement; provided that the
provisions of the immediately preceding clause (ii) shall not apply if the
Enforcing Party elects to grant the Nonenforcing Party enforcement rights with
respect to such infringement. The Enforcing Party will not grant a license to
any such infringing Third Party with respect to any directly competitive
infringing product on terms materially more favorable (milestones and royalties)
than the terms of the license granted hereunder to the Nonenforcing Party or,
solely with
17
respect to the Affected Product, will adjust the terms of such license so that
they are not materially less favorable than the terms of the license granted to
the infringing Third Party.
(I) Except as otherwise agreed to by the Parties as part of a
cost-sharing arrangement, any recovery realized as a result of such litigation,
after reimbursement of any reasonable litigation expenses of Isis and Alnylam,
shall be retained by the Party or Parties that brought and controlled such
litigation for purposes of this Agreement, except that any recovery realized as
a result of such litigation shall be treated as Net Sales of Isis Products or
Net Sales of Alnylam Products and distributed as such Net Sales would have been
distributed.
11.6 Manufacturing Patents. All provisions relating to Manufacturing
Patents shall be governed by the Manufacturing Services Agreement.
11.7 Third Party Patents. The Parties will consult about the need to
license any patents Controlled by Third Parties that would be useful or
necessary for either Party to research, develop, make, have made, use, sell,
offer for sale or import Double Stranded RNA Products. If it is agreed that
there is a desire to obtain a license or to acquire any such patent, the Parties
will negotiate in good faith regarding (i) the share of the financial
obligations relating to the license or acquisition that each Party will bear;
(ii) the compensation of any acquisition costs incurred in connection with
obtaining the Patent rights; and (iii) an agreement by the Parties to abide by
all terms of the agreement under which the patent rights are granted.
11.8 Future Licenses. If after the Effective Date, a Party (the
"Controlling Party") later invents or acquires rights or title to an invention
claimed by a Patent that (i) would be included in the Isis Future Chemistry
Patents or Isis Future Motif and Mechanism Patents if such Party is Isis or in
the Alnylam Future Chemistry Patents or Alnylam Future Motif and Mechanism
Patents if such Party is Alnylam (the "Additional Rights") and (ii) carry
financial or other obligations, then the Controlling Party must promptly notify
the non-Controlling Party of such acquisition or invention. If the
non-Controlling Party wishes to include such Additional Rights under the
licenses granted pursuant to Article 5 or 6, as applicable, the non-Controlling
Party will notify the Controlling Party of its desire to do so and will assume
all financial and other obligations to the Controlling Party's licensors or
collaborators, if any, arising from the grant to the non-Controlling Party of
such license. Any Additional Rights that do not carry financial or other
obligations shall be automatically included under the licenses granted pursuant
to Article 5 or 6, as applicable. If a Party pays any upfront payments or
similar acquisition costs to access Additional Rights, the Parties will
negotiate in good faith regarding sharing such acquisition costs and payments.
When acquiring or creating such Additional Rights, each Party will endeavor in
good faith to secure the right to sublicense such Additional Rights to the other
Party.
ARTICLE 12
18
CONFIDENTIALITY
12.1 Nondisclosure Obligation. All Confidential Information disclosed by
one Party to the other Party hereunder will be maintained in confidence by the
receiving Party and will not be disclosed to a Third Party or Affiliate or used
for any purpose except as set forth below.
12.2 Permitted Disclosures. Except as otherwise provided herein, a Party
may disclose Confidential Information received from the other Party:
(A) to governmental or other regulatory agencies in order to obtain
Patents or approval to conduct clinical trials, or to gain Marketing Approval;
provided that such disclosure may be made only to the extent reasonably
necessary to obtain such Patents or approvals;
(B) to any adjudicative body as required by law, provided that prior
to such disclosure, the Party subject to such disclosure obligation (the
"Notifying Party") promptly notifies the other Party of such requirement so that
such other Party can seek a protective order, confidential treatment or other
appropriate remedy; and provided, further, that in the event that no such
protective order, confidential treatment or other remedy is obtained, or that
such other Party waives compliance with this section, the Notifying Party will
furnish only that portion of the other Party's Confidential Information that it
is advised by counsel it is legally required to furnish;
(C) to Affiliates, sublicensees, agents, consultants, and/or other
Third Parties for the development, manufacturing and/or marketing of Isis
Products or Alnylam Products (or for such parties to determine their interest in
performing such activities) in accordance with this Agreement on the condition
that such Affiliates, sublicensees and Third Parties agree to be bound by the
confidentiality obligations contained in this Agreement;
(D) if such disclosure is required by law or regulation (including
without limitation by rules or regulations of any securities exchange or
NASDAQ), provided that prior to such disclosure, the Notifying Party promptly
notifies the other Party of such requirement so that such other Party can seek a
protective order, confidential treatment or other appropriate remedy; and
provided, further, that in the event that no such protective order, confidential
treatment or other remedy is obtained, or that such other Party waives
compliance with this section, the Notifying Party will furnish only that portion
of the other Party's Confidential Information that it is advised by counsel it
is legally required to furnish; or
(E) as necessary if embodied in products to develop and
commercialize such products.
Either Party may disclose (i) a copy of this Agreement on a confidential basis
to prospective lenders and investors, (ii) a mutually agreed upon redacted copy
of this Agreement on a confidential basis to prospective collaborators and (iii)
the terms of this Agreement as required under applicable securities laws or
regulations (including without limitation under rules or regulations of any
securities exchange or NASDAQ); provided, however, that,
19
subject to Section 6.4(i), Alnylam shall not disclose Isis' past or current
Reserved Targets without the express prior written consent of Isis.
12.3 Announcements; Publicity.
(A) Each Party understands that this Agreement is likely to be of
significant interest to investors, analysts and others, and that either Party
therefore may make public announcements with respect to this Agreement. The
Parties agree that any such announcement will not contain confidential business
or technical information unless disclosure of confidential business or technical
information is required by law or regulation, in which case they will make
reasonable efforts to minimize such disclosure of confidential business or
technical information to that required by law or regulation. Each Party agrees
to provide to the other Party a copy of any such public announcement as soon as
reasonably practicable under the circumstances prior to its scheduled release.
Except under extraordinary circumstances, each Party shall provide the other
with an advance copy of any press release at least two (2) business days prior
to the scheduled disclosure. The other Party shall have the right to
expeditiously review and recommend changes to any announcement regarding this
Agreement or the subject matter of this Agreement, provided that such right of
review and recommendation shall only apply for the first time that specific
information is to be disclosed, and shall not apply to the subsequent disclosure
of information that (i) is substantially similar to a previously reviewed
disclosure and (ii) in the context of the subsequent disclosure, does not carry
a substantially different qualitative message than that carried by the
previously reviewed disclosure. The Party whose press release has been reviewed
shall in good faith consider any changes that are timely recommended by the
reviewing Party.
(B) Each Party will (i) use reasonable, good faith efforts to provide the
other Party with at least 5 business days' prior notice (which notice may be
given orally to a senior executive officer of the other Party) before such Party
publicly announces the execution of a Naked Sublicense, Bona Fide Drug Discovery
Collaboration agreement or Development Collaboration agreement (or any material
amendments thereto) that could reasonably be expected to be of strategic or
financial importance to the other Party's business and (ii) cooperate with the
other Party to enable the other Party to develop appropriate mutually beneficial
public announcements regarding such transactions.
ARTICLE 13
INDEMNIFICATION
13.1 Indemnification by Alnylam. Alnylam will indemnify, defend and hold
Isis and its agents, employees, officers and directors (the "Isis Indemnitees")
harmless from and against any and all liability, damage, loss, cost or expense
(including reasonable attorneys' fees) arising out of Third Party claims or
suits related to (a) Alnylam's performance of its obligations under this
Agreement; (b) breach by Alnylam of its representations and warranties set forth
in Article 15; or (c) the discovery, development, manufacture, use, importation
or commercialization (including marketing and sale) of Alnylam Products.
20
13.2 Indemnification by Isis. Isis will indemnify, defend and hold Alnylam
and its Affiliates and each of their respective agents, employees, officers and
directors (the "Alnylam Indemnitees") harmless from and against any and all
liability, damage, loss, cost or expense (including reasonable attorneys' fees)
arising out of Third Party claims or suits related to (a) Isis' performance of
its obligations under this Agreement; (b) breach by Isis of its representations
and warranties set forth in Article 15; or (c) the discovery, development,
manufacture, use, importation or commercialization (including marketing and
sale) of Isis Products.
13.3 Notification of Claims; Conditions to Indemnification Obligations. A
Party entitled to indemnification under this Article 13 shall (a) promptly
notify the other Party as soon as it becomes aware of a claim or action for
which indemnification may be sought pursuant hereto, (b) cooperate with the
indemnifying Party in the defense of such claim or suit, and (c) permit the
indemnifying Party to control the defense of such claim or suit, including
without limitation the right to select defense counsel; provided that if the
Party entitled to indemnification fails to promptly notify the indemnifying
Party pursuant to the foregoing clause (a), the indemnifying Party shall only be
relieved of its indemnification obligation to the extent prejudiced by such
failure. In no event, however, may the indemnifying Party compromise or settle
any claim or suit in a manner which admits fault or negligence on the part of
the indemnified Party, or which imposes obligations on the indemnified Party
other than financial obligations that are covered by the indemnifying Party's
indemnification obligation, without the prior written consent of the indemnified
Party. The indemnifying Party will have no liability under this Article 13 with
respect to claims or suits settled or compromised without its prior written
consent.
ARTICLE 14
TERM AND TERMINATION OF AGREEMENT
14.1 Term and Termination of Agreement. This Agreement will be effective
as of the Effective Date and unless terminated earlier pursuant to Sections 14.2
or 14.3 below, the term of this Agreement will continue in effect until
expiration of the License Term.
14.2 Termination upon Material Breach. This Agreement may be terminated
upon written notice by either Party to the other at any time during the term of
this Agreement if the other Party is in material breach of its obligations
hereunder and has not cured such breach within 90 days after written notice
requesting cure of the breach; provided, however, that (a) in the event of a
good faith dispute with respect to the existence of such a material breach, the
90-day cure period will be stayed until such time as the dispute is resolved
pursuant to Section 17.6 hereof, (b) so long as the breaching Party takes
substantial steps to cure the breach promptly after receiving notice of the
breach from the non-breaching Party and thereafter diligently prosecutes the
cure to completion as soon as is practicable, the non-breaching Party may not
terminate this Agreement, and (c) any license granted under this Agreement with
respect to an Isis or Alnylam Product that has at least reached IND-Enabling
Studies may not be terminated for a material breach under this Section 14.2
(except for an uncured failure to make any undisputed portion of any payment
obligation under Article 7 or
21
8 with respect to such Isis or Alnylam Product) to the extent such license is
necessary to develop, make and have made, sell and import such Isis or Alnylam
Product.
14.3 Termination upon Bankruptcy; Rights in Bankruptcy.
(A) This Agreement may be terminated with written notice by either
Party at any time during the term of this Agreement upon the filing or
institution of bankruptcy, reorganization, liquidation or receivership
proceedings by or against the other Party or upon an assignment of a substantial
portion of its assets for the benefit of creditors by the other Party; provided,
however, in the case of any involuntary bankruptcy proceeding such right to
terminate will only become effective if the Party consents to the involuntary
bankruptcy or such proceeding is not dismissed within 90 days of the filing
thereof.
(B) All rights and licenses granted under or pursuant to this
Agreement by Isis or Alnylam are, and will otherwise be deemed to be, for
purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to
"intellectual property" as defined under Section 101 of the U.S. Bankruptcy
Code. The Parties agree that the Parties, as licensees of such rights under this
Agreement, will retain and may fully exercise all of their rights and elections
under the U.S. Bankruptcy Code. The Parties further agree that, in the event of
the commencement of a bankruptcy proceeding-by or against either Party under the
U.S. Bankruptcy Code, the Party hereto which is not a Party to such proceeding
will be entitled to a complete duplicate of (or complete access to, as
appropriate) any such intellectual property and all embodiments of such
intellectual property, and same, if not already in their possession, will be
promptly delivered to them (i) upon any such commencement of a bankruptcy
proceeding upon their written request therefore, unless the Party subject to
such proceeding elects to continue to perform all of its obligations under this
Agreement, or (ii) if not delivered under (i) above, following the rejection of
this Agreement by or on behalf of the Party subject to such proceeding upon
written request therefore by the non-subject Party.
14.4 Accrued Rights and Surviving Obligations.
(A) Expiration or termination of the Agreement will not relieve the
Parties of any obligation accruing prior to such expiration or termination,
including, but not limited to, financial obligations under Article 7 or 8.
Sections 9.2, 9.3 and 11.1, and Articles 1, 12, 13, 14 and 17 will survive
expiration or termination of the Agreement. Provisions concerning reporting
requirements will continue in effect in accordance with any applicable
timetables set forth herein. Any expiration or early termination of this
Agreement will be without prejudice to the rights of either Party against the
other accrued or accruing under this Agreement prior to termination. No
expiration of this Agreement will relieve a Party of its obligation to pay
milestones, royalties, or a percentage of Technology Access Fees or Sublicense
Revenue.
(B) The rights of any sublicensee under any permitted sublicense
granted in accordance with Section 5.2 or 6.3 will survive the termination of
this Agreement.
22
ARTICLE 15
REPRESENTATIONS AND WARRANTIES; DISCLAIMER
15.1 Representations and Warranties of the Parties. Each Party represents
and warrants to the other Party that, as of the date of this Agreement:
(A) Such Party is duly organized and validly existing under the laws
of the state of its incorporation and has full corporate power and authority to
enter into this Agreement and to carry out the provisions hereof;
(B) Such Party has taken all corporate action necessary to authorize
the execution and delivery of this Agreement and the performance of its
obligations under this Agreement;
(C) This Agreement is a legal and valid obligation of such Party,
binding upon such Party and enforceable against such Party in accordance with
the terms of this Agreement. The execution, delivery and performance of this
Agreement by such Party does not conflict with any agreement, instrument or
understanding, oral or written, to which such Party is a Party or by which such
Party may be bound, and does not violate any law or regulation of any court,
governmental body or administrative or other agency having authority over such
Party. All consents, approvals and authorizations from all governmental
authorities or other Third Parties required to be obtained by such Party in
connection with this Agreement have been obtained;
(D) Such Party has sufficient right, power and authority to enter
into this Agreement, to perform its obligations under this Agreement and to
grant the licenses granted hereunder.
15.2 Disclaimers. THE PARTIES EXPRESSLY DISCLAIM ALL WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS
FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF THIRD PARTY RIGHTS, UNLESS
OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT.
ARTICLE 16
NOTICE
16.1 Notice. All notices which are required or permitted hereunder will be
in writing and sufficient if delivered personally, sent by facsimile (and
confirmed by telephone), sent by nationally-recognized overnight courier or sent
by registered or certified mail, postage prepaid, return receipt requested,
addressed as follows:
if to Isis, to: Isis Pharmaceuticals, Inc.
Carlsbad Research Center
0000 Xxxxxxx Xxxxxx
Xxxxxxxx, XX 00000
23
Attention: Executive Vice President
Fax No.: x0 (000) 000-0000
with a copy to: Attention: General Counsel
Fax No.: x0 (000) 000-0000
if to Alnylam, to: Alnylam Pharmaceuticals, Inc.
000 Xxxxxxxx Xxxxx, Xxxxx 000
Xxxxxxxxx, XX 00000
Attention: President
Fax No.: x0 (000) 000-0000
with a copy to: Xxxx and Xxxx LLP
00 Xxxxx Xxxxxx
Xxxxxx, Xxxxxxxxxxxxx 00000
Attention: Xxxxxx X. Xxxxxx, Esq.
Fax No.: x0 (000) 000-0000
or to such other address as the Party to whom notice is to be given may have
furnished to the other Party in writing in accordance herewith. Any such notice
will be deemed to have been given when delivered if personally delivered or sent
by facsimile on a business day, on the business day after dispatch if sent by
nationally-recognized overnight courier and on the third business day following
the date of mailing if sent by mail.
ARTICLE 17
MISCELLANEOUS PROVISIONS
17.1 Relationship of the Parties. It is expressly agreed that Isis and
Alnylam will be independent contractors and that the relationship between the
two Parties will not constitute a partnership, joint venture or agency. Neither
Isis nor Alnylam will have the authority to make any statements, representations
or commitments of any kind, or to take any action, which will be binding on the
other, without the prior consent of the other Party.
17.2 Successors and Assigns.
(A) Neither this Agreement nor any interest hereunder may be
assigned or otherwise transferred (whether by sale of stock, sale of assets or
merger), nor, except as expressly provided hereunder, may any right or
obligations hereunder be assigned or transferred by either Party without the
prior written consent of the other Party; provided, however, that a Party may,
without such consent, assign this Agreement and its rights and obligations
hereunder to an Affiliate or in connection with an Acquisition.
(B) Notwithstanding the provisions of Section 17.2(a), if Alnylam is
the subject of an Acquisition and the entity surviving the acquisition does not
maintain [**] that is substantially similar or greater [**] after the time of
the Acquisition, then (i) the limit on the [**] that Isis can [**] pursuant to
Section 6.4(a) will [**] and (ii) the exclusive right to grant Naked
Sublicenses under Section 5.2 will [**].
(C) Notwithstanding the provision of Section 17.2(a), if Isis is the
subject of an Acquisition, (i) the entity surviving such Acquisition will no
longer [**] under Section 6.4(a) and (ii) the number of [**] such Acquisition
will be permitted to [**] pursuant to Section 6.4(a) shall be limited to [**]
per calendar year.
24
(D) Any permitted assignee will assume all obligations of its
assignor under this Agreement. Any attempted assignment not in accordance with
this Section 17.2 will be void.
17.3 Entire Agreement; Amendments. This Agreement, together with the
Equity Documents, contains the entire understanding of the Parties with respect
to the license, development and commercialization of Products hereunder. All
express or implied agreements and understandings, either oral or written,
heretofore made by the Parties on the same subject matter are expressly
superseded by this Agreement. This Agreement may be amended, or any term hereof
modified, only by a written instrument duly executed by both Parties hereto.
17.4 Force Majeure. Neither Party will be held liable or responsible to
the other Party nor be deemed to have defaulted under or breached this Agreement
for failure or delay in fulfilling or performing any term of this Agreement when
such failure or delay is caused by or results from causes beyond the reasonable
control of the affected Party including, without limitation, embargoes, acts of
war (whether war be declared or not), insurrections, riots, civil commotions,
acts of terrorism, strikes, lockouts or other labor disturbances, or acts of
God. The affected Party will notify the other Party of such force majeure
circumstances as soon as reasonably practical and will make every reasonable
effort to mitigate the effects of such force majeure circumstances.
17.5 Applicable Law. The Agreement will be governed by and construed in
accordance with the laws of the State of Delaware without reference to any rules
of conflict of laws.
17.6 Dispute Resolution.
(A) The Parties recognize that disputes may from time to time arise
between the Parties during the term of this Agreement. In the event of such a
dispute, either Party, by written notice to the other Party, may have such
dispute referred to the Parties' respective executive officers designated below
or their successors, for attempted resolution by good faith negotiations within
30 days after such notice is received. Said designated officers are as follows:
For Isis: Executive Vice President
For Alnylam: Senior Vice President of Business Development
If the dispute is not resolved as provided above, the President of Isis and the
President of Alnylam will meet for attempted resolution by good faith
negotiations within 15 days after the expiration of the preceding 30 day period.
(B) In the event the designated executive officers are not able to
resolve such dispute during such 15-day period, then any such dispute shall be
resolved through binding arbitration under the Commercial Arbitration Rules of
the American Arbitration Association by a panel of three arbitrators appointed
in accordance with such rules. The Parties shall be entitled to the same
discovery as permitted under the U.S. Federal Rules of Civil Procedure; provided
that the panel shall be entitled in its discretion to grant a request
25
from a Party for expanded or more limited discovery. The award of the
arbitrators shall be the sole and exclusive remedy between the Parties regarding
any such dispute. An award rendered in connection with an arbitration pursuant
to this Section 17.6 shall be final and binding upon the Parties and any
judgment upon such award may be entered and enforced in any court of competent
jurisdiction. Any arbitration pursuant to this Section 17.6 shall be conducted
in San Diego, California if Alnylam initiates the arbitration or in Boston,
Massachusetts if Isis initiates the arbitration. Nothing in this Section 17.6
shall be construed as limiting in any way the right of a Party to seek an
injunction or other equitable relief with respect to any actual or threatened
breach of this Agreement or to bring an action in aid of arbitration. Should any
Party seek an injunction or other equitable relief, or bring an action in aid of
arbitration, then for purposes of determining whether to grant such injunction
or other equitable relief, or whether to issue any order in aid of arbitration,
the dispute underlying the request for such injunction or other equitable
relief, or action in aid of arbitration, may be heard by the court in which such
action or proceeding is brought.
17.7 No Consequential Damages. IN NO EVENT WILL EITHER PARTY OR ANY OF ITS
RESPECTIVE AFFILIATES BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR
SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT,
WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING, BUT NOT
LIMITED TO, LOSS OF PROFITS OR REVENUE, OR CLAIMS OF CUSTOMERS OF ANY OF THEM OR
OTHER THIRD PARTIES FOR SUCH OR OTHER DAMAGES.
17.8 Captions. The captions to the several Articles and Sections hereof
are not a part of this Agreement, but are merely a convenience to assist in
locating and reading the several Articles and Sections hereof.
17.9 Waiver. The waiver by either Party hereto of any right hereunder, or
the failure to perform, or a breach by the other Party will not be deemed a
waiver of any other right hereunder or of any other breach or failure by said
other Party whether of a similar nature or otherwise.
17.10 Compliance with Law. Nothing in this Agreement will be deemed to
permit a Party to export, re-export or otherwise transfer any Product sold under
this Agreement without compliance with applicable laws.
17.11 Severability. In the event any one or more of the provisions
contained in this Agreement should be held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining
provisions contained herein will not in any way be affected or impaired thereby,
unless the absence of the invalidated provision(s) adversely affect the
substantive rights of the Parties. The Parties will in such an instance use
their best efforts to replace the invalid, illegal or unenforceable provision(s)
with valid, legal and enforceable provision(s) which, insofar as practical,
maintains the balance of the rights and obligations of the Parties under this
Agreement.
17.12 Waiver of Rule of Construction. Each Party has had the opportunity
to consult with counsel in connection with the review, drafting and negotiation
of this
26
Agreement. Accordingly, the rule of construction that any ambiguity in this
Agreement will be construed against the drafting Party will not apply.
17.13 Counterparts. This Agreement may be executed in two or more
counterparts, each of which will be deemed an original, but all of which
together will constitute one and the same instrument.
17.14 Performance by Affiliates. To the extent that this Agreement imposes
obligations on Affiliates of a Party, such Party agrees to cause its Affiliates
to perform such obligations.
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the
Effective Date.
ISIS PHARMACEUTICALS, INC. ALNYLAM PHARMACEUTICALS, INC.
By: /s/ B. Xxxxx Xxxxxxxx By: /s/ Xxxxxxx X. Xxxxx
-------------------------------- ---------------------------------
Name: B. Xxxxx Xxxxxxxx Name: Xxxxxxx X. Xxxxx
------------------------------- -------------------------------
Title: Executive Vice President Title: Senior Vice President,
------------------------------ ------------------------------
Business Development
------------------------------
27
EXHIBIT 1.1
DEFINITIONS
1. "Acquisition" means any of the following events: (a) the acquisition by
any Person or group, other than a Person or group controlling such Party
as of the Effective Date, of "beneficial ownership" (as defined in Rule
13d-3 under the United States Securities Exchange Act of 1934, as
amended), directly or indirectly, of fifty percent (50%) or more of the
shares of such Party's voting stock; (b) the approval by the shareholders
of such Party of a merger, share exchange, reorganization, consolidation
or similar transaction of such Party (a "Transaction"), other than a
Transaction which would result in the voting stock of such Party
outstanding immediately prior thereto continuing to represent (either by
remaining outstanding or by being converted into voting securities of the
surviving entity) more than fifty percent (50%) of the voting stock of
such Party or such surviving entity immediately after such Transaction; or
(c) approval by the shareholders of such Party of a complete liquidation
of such Party or a sale or disposition of all or substantially all of the
assets of such Party.
2. "Active Program" means with respect to a Gene Target, any ongoing drug
discovery, development, or commercialization of a compound directed to
such Gene Target.
3. "Affiliate" with respect to either Party means Person controlling,
controlled by, or under common control with such Party. For purposes of
this definition, "control" refers to the possession, directly or
indirectly, of the power to direct the management or policies of a Person,
whether through the ownership of voting securities, by contract or
otherwise, of a Person.
4. "Alnylam Current Chemistry Patents" means all Chemistry Patents Controlled
by Alnylam as of the Effective Date, including without limitation the
Patents listed on Schedule 1-4 attached to the Addendum Transmittal,
except Patents that constitute Alnylam Excluded Technology.
5. "Alnylam Current Motif and Mechanism Patents" means all Motif and
Mechanism Patents Controlled by Alnylam as of the Effective Date,
including without limitation the Patents listed on Schedule 1-5 attached
to the Addendum Transmittal, except Patents that constitute Alnylam
Excluded Technology.
6. "Alnylam Excluded Technology" means inhibitors to specific genes or gene
families, manufacturing and analytical technologies, formulation and
delivery technologies and the specific technology listed on Schedule 1-6
attached to the Addendum Transmittal.
7. "Alnylam Future Chemistry Patents" means all Chemistry Patents Controlled
by Alnylam after the Effective Date and having an earliest priority date
of no later than [**] years from the Effective Date or that is necessary
to practice a Patent licensed hereunder; provided, however that (a) for
any such Chemistry Patents
28
that are acquired, licensed or invented that include financial or other
obligations to a Third Party, the provisions of Section 11.8 will govern
whether such Patent will be included as an Alnylam Future Chemistry Patent
and (b) Alnylam Future Chemistry Patents do not include Patents that
constitute Alnylam Excluded Technology.
8. "Alnylam Future Motif and Mechanism Patents" means all Motif and Mechanism
Patents Controlled by Alnylam after the Effective Date and having an
earliest priority date of no later than [**] years from the Effective Date
or that is necessary to practice a Patent licensed hereunder; provided,
however that (a) for any such Motif and Mechanism Patents that are
acquired, licensed or invented that include financial or other obligations
to a Third Party, the provisions of Section 11.8 will govern whether such
Patent will be included as an Alnylam Future Motif and Mechanism Patent
and (b) Alnylam Future Motif and Mechanism Patents do not include Patents
that constitute Alnylam Excluded Technology.
9. "Alnylam Patent Rights" means Alnylam Current Motif and Mechanism Patents,
Alnylam Future Motif and Mechanism Patents, Alnylam Current Chemistry
Patents and Alnylam Future Chemistry Patents.
10. "Alnylam Product" means a Double Stranded RNA Product or MicroRNA Product
discovered or developed by Alnylam, its Affiliates or sublicensees, the
manufacture, sale or use of which is covered by a Valid Claim within the
Isis Patent Rights.
11. "Antisense Drug Discovery Program" means an antisense drug discovery
program that investigates multiple different mechanisms of modulating a
Gene Target to identify a drug candidate, with a predominant emphasis on
potential drug candidates that are single-stranded.
12. "Bona Fide Drug Discovery Collaboration" means a collaboration involving
the discovery and development of Double Stranded RNA Products in which a
Party plays an integral role in the experimentation and an important,
though not necessarily dominant or co-equal, role in the decision-making,
relating to the discovery and development of Double Stranded RNA Products
from the point in time at which the relevant Gene Target has been
designated through the initiation of [**]. A Bona Fide Drug Discovery
Collaboration may continue beyond the initiation of such [**]. For Isis
Products that are Double Stranded RNA Products, a Bona Fide Drug Discovery
Collaboration must be an Antisense Drug Discovery Program. For each Party,
collaborations that do not include or involve Patents licensed from the
other Party hereunder shall not constitute Bona Fide Drug Discovery
Collaborations. A Party's experimentation relating to the discovery and
development of Double Stranded RNA Products that modulate a relevant Gene
Target prior to the commencement of a collaboration shall be deemed to
have been conducted in the course of the collaboration for purposes of
determining whether the collaboration is a Bona Fide Drug Discovery
Collaboration. A series of related collaborations and/or license
agreements involving the discovery and development of Double
29
Stranded RNA Products with the same sublicensee or related sublicensees
that includes a Bona Fide Drug Discovery Collaboration agreement will be
aggregated to constitute a single Bona Fide Drug Discovery Collaboration.
13. "Chemistry Patent" means any Patent that covers (a) an oligomeric compound
having a chemical composition that differs from a native oligonucleotide
composition or (b) any modification to the base, sugar or internucleoside
linkage of the oligomeric compound, and specifically, but without
limitation, includes covalently linked conjugates and other such moieties.
14. "Commercially Reasonable Efforts" means the diligent efforts, expertise
and resources normally used by a Party to develop, manufacture and
commercialize a product or compound owned by it or to which it has rights,
which is of similar market potential at a similar stage in its development
or product life, taking into account issues of safety, and efficacy,
product profile, difficulty in developing the product or compound,
competitiveness of the marketplace for the product, the proprietary
position of the compound or product, the regulatory structure involved,
the potential total profitability of the applicable product(s) marketed or
to be marketed and other relevant factors affecting the cost, risk and
timing of development and the total potential reward to be obtained if a
product is commercialized, but not less than reasonably diligent efforts.
In determining whether Commercially Reasonable Efforts have been
satisfied, the fact that a Party is required to pay the other Party a
royalty or milestones shall not be a factor weighed (i.e., a Party may not
apply lesser resources or effort to a Product because it must pay a
royalty or milestones to the other Party).
15. "Control" or "Controlled" means, with respect to any Patent or other
intellectual property right, possession of the right (whether by
ownership, license or otherwise), to assign, or grant a license,
sublicense or other right to or under, such Patent or right as provided
for herein without violating the terms of any agreement or other
arrangement with any Third Party.
16. "Confidential Information" means information which is (a) of a
confidential and proprietary nature; and (b) not readily available to that
Party's competitors and which, if known by a competitor of that Party,
might lessen any competitive advantage of that Party or give such
competitor a competitive advantage.
Confidential Information includes, without limitation, (x) information
that is proprietary or confidential or which is treated by that Party as
confidential and which relates either directly or indirectly to the
business of that Party regardless of the form in which that information is
constituted, and which is not lawfully in the public domain; and (y) any
confidential information in relation to Patents, technology, know-how, or
any improvements owned or Controlled by a Party hereto.
Confidential Information will not include any information that the
receiving Party can establish by written records:
30
(i) was known by it prior to the receipt of Confidential Information
from the disclosing Party;
(ii) was disclosed to the receiving Party by a Third Party having the
right to do so;
(iii) was, or subsequently became, in the public domain through no fault
of the receiving Party, its officers, directors, employees or
agents; or
(iv) was concurrently or subsequently developed by personnel of the
receiving Party without having had access to the disclosing Party's
Confidential Information.
17. "Development Collaboration" means a collaboration by either Party with a
Third Party whose purpose is the further development and/or
commercialization of a Double Stranded RNA Product and that begins at or
after the initiation of IND-Enabling Studies for such Product. For each
Party, collaborations that do not include or involve Patents licensed from
the other Party hereunder shall not constitute Development Collaborations.
18. "Double Stranded RNA" means a composition designed to act primarily
through an RNAi mechanism that is not a MicroRNA Construct and which
consists of either (a) two separate oligomers of native or chemically
modified RNA that are hybridized to one another along a substantial
portion greater than or equal to [**] of their lengths, or (b) a single
oligomer of native or chemically modified RNA that is hybridized to itself
by self-complementary base-pairing along a substantial portion (greater
than or equal to) [**] of its length to form a hairpin.
19. "Double Stranded RNA Product" means a pharmaceutical composition that
contains a Double Stranded RNA.
20. "Equity Documents" means the Series D Convertible Preferred Stock Purchase
Agreement and the Investor Rights Agreement by and between the Parties
executed as of the Effective Date.
21. "Gene Target" means a transcriptional unit of a gene, including any
protein product of such transcriptional unit, and including all splice
variants.
22. "IND" means an Investigational New Drug Application or similar foreign
application or submission for approval to conduct human clinical
investigations.
23. "IND-Enabling Studies" means the pharmacokinetic and toxicology studies
required to meet the regulations for filing an IND.
24. "Initiation of Phase I Trial" means the dosing of the first patient in the
first human clinical trial conducted and designed to evaluate safety of a
product.
31
25. "Initiation of Phase III Trial" means the dosing of the first patient in
the first pivotal human clinical trial the results of which could be used
to establish safety and efficacy of a Product as a basis for an
application for marketing approval or that would otherwise satisfy the
requirements of 21 CFR 3 12.21I or its foreign equivalent.
26. "Isis Co-Exclusive Target" has the meaning set forth in Section 6.4(b).
27. "Isis Current Chemistry Patents" means all Chemistry Patents Controlled by
Isis as of the Effective Date, including without limitation the Patents
listed on Schedule 1-27 attached to the Addendum Transmittal, except
Patents that constitute Isis Excluded Technology.
28. "Isis Current Motif and Mechanism Patents" means all Motif and Mechanism
Patents Controlled by Isis as of the Effective Date, including without
limitation the Patents listed on Schedule 1-28 attached to the Addendum
Transmittal, except Patents that constitute Isis Excluded Technology.
29. "Isis Encumbered Target" means a Gene Target (a) to which Isis has a
contractual obligation to a Third Party existing as of the Effective Date
that precludes Isis from granting a license under Section 5 with respect
to such Gene Target and (b) that is identified and described on a [**] (as
defined in the letter agreement dated March 9, 2004 between Alnylam and
Isis). When and if such restrictions lapse a Gene Target will cease to be
an Isis Encumbered Target. When and if such restrictions lapse a Gene
Target will cease to be an Isis Encumbered Target.
30. "Isis Excluded Technology" means (a) RNase H mechanisms, RNase H motifs
and RNase H oligonucleotides when utilized in an RNase H mechanism, assays
and methods thereof; (b) modulators of specific genes, gene families or
proteins; (c) manufacturing technologies; (d) analytical technologies,
kits and assays, including without limitation methods, systems and
compositions of matter for amplifying, quantifying, detecting,
characterizing or identifying nucleic acids or nonoligomeric ligands
thereto; (e) formulation and delivery technologies; and (f) the specific
technology listed on Schedule 1-30 attached to the Addendum Transmittal.
31. "Isis Exclusive Target" has the meaning set forth in Section 6.4(b).
32. "Isis Future Motif and Mechanism Patents" means all Motif and Mechanism
Patents Controlled by Isis after the Effective Date and having an earliest
priority date of no later than [**] years from the Effective Date or that
is necessary to practice a Patent licensed hereunder; provided, however
that (a) for any such Motif and Mechanism Patents that are acquired,
licensed or invented that include financial or other obligations to a
Third Party, the provisions of Section 11.8 will govern whether such
Patent will be included as an Isis Future Motif Mechanism Patent and (b)
Isis Future Motif and Mechanism Patents do not include Patents that
constitute Isis Excluded Technology.
33. "Isis Future Chemistry Patents" means the Chemistry Patents Controlled by
Isis after the Effective Date and having an earliest priority date of no
later than [**]
32
years from the Effective Date or that is necessary to practice a Patent
licensed hereunder; provided, however that (a) for any such Chemistry
Patents that are acquired, licensed or invented that include financial or
other obligations to a Third Party, the provisions of Section 11.8 will
govern whether such Chemistry Patents will be included as an Isis Future
Chemistry Patent, except Patents that constitute Isis Excluded Technology
and (b) Isis Future Chemistry Patents do not include Patents that
constitute Isis Excluded Technology.
34. "Isis Manufacturing Patents" means the Patents specifically listed on
Schedule 1-34 attached to the Addendum Transmittal. The Parties may agree
in writing from time to time to add additional Patents to Schedule 1-34
attached to the Addendum Transmittal.
35. "Isis Patent Rights" means Isis Current Motif and Mechanism Patents, Isis
Future Motif and Mechanism Patents, Isis Current Chemistry Patents and
Isis Future Chemistry Patents.
36. "Isis Product" means any Isis Single Stranded Product, MicroRNA Product or
Double Stranded RNA Product, discovered or developed by Isis, its
Affiliates or sublicensees, the manufacture, sale or use of which is
covered by a Valid Claim within the Alnylam Patent Rights.
37. "Isis Single Stranded Product" means any single stranded oligomeric
compound (a) that hybridizes in whole or in part with a target RNA and
modulates the Gene Target, (b) is not a Double Stranded RNA or Double
Stranded RNA Product and (c) the manufacture, sale or use of which is
covered by a Valid Claim within the Alnylam Patent Rights.
38. "Joint Invention" has the meaning set forth in Section 11.1(b).
39. "Joint Patent" has the meaning set forth in Section 11.1(b).
40. "Know-How" means all tangible or intangible know-how, discoveries,
processes, formulas, data, clinical and preclinical results, non-Patented
Inventions, Inventions for which Patents are in preparation, trade
secrets, and any physical, chemical, or biological material or any
replication of any such material in whole or in part that are not
otherwise covered by the Isis Patent Rights or the Alnylam Patent Rights
41. "License Term" means the period from the Effective Date until the date of
expiry of the last to expire of the Patents licensed hereunder.
42. "Major Pharmaceutical Company" means a Person that, together with all of
its affiliated Persons, had annual pharmaceutical product sales during the
most recently completed calendar year in excess of $[**].
43. "Manufacturing Services Agreement" has the meaning set forth in Section
3.1.
33
44. "Marketing Approval" means the act of a Regulatory Authority necessary for
the marketing and sale of the Product in a country or regulatory
jurisdiction, including, without limitation, the approval of the NDA by
the FDA, EC Approval, and Japanese Approval.
45. "MicroRNA Construct" is a construct having the chemical and physical
description of a Double Stranded RNA that is either (a) designed to target
a[**]precursor microRNA or a microRNA, thereby to inhibit the production
or function of the microRNA, or (b) designed to function by mimicking the
translational repressor function of a naturally occurring microRNA, and
which, in relation to its target RNA, has been demonstrated in vitro and,
to the extent reasonably feasible, in vivo, to function solely as a
translational repressor and not via cleavage of such target RNA.
46. "MicroRNA Product" means a pharmaceutical product that contains a MicroRNA
Construct.
47. "Motif and Mechanism Patents" means any Patent that covers an oligomeric
structure or composition of matter, or any method of using or
incorporating such oligomeric structure or composition of matter in vitro
or in vivo, including without limitation for therapeutic use, in which
target RNA levels are modulated by any mechanism other than RNase H.
48. "Naked Sublicense" means a license for Double Stranded RNA that includes
rights to the Isis Patent Rights that is not a license in connection with
(a) a Development Collaboration or (b) a Bona Fide Drug Discovery
Collaboration. A series of Naked Sublicenses to the same sublicensee or
related sublicensees will be aggregated to constitute a single Naked
Sublicense. For the avoidance of doubt, where this Agreement grants
Alnylam exclusive rights to grant Naked Sublicenses, such exclusive rights
preclude Isis from granting licenses to the Isis Patent Rights to Third
Parties for Double Stranded RNA even though such license grants by Isis
would technically be license grants and not sublicense grants. Licenses
that do not include or involve rights to Isis Patents shall not constitute
Naked Sublicenses.
49. "Naked Sublicensee" means a Third Party that obtains a Naked Sublicense
from Alnylam in accordance with the terms of this Agreement.
50. "NDA" means New Drug Application or similar application or submission for
approval to market and sell a new pharmaceutical product filed with or
submitted to a Regulatory Authority.
51. "Net Sales" will mean the gross invoice price of Products sold by Alnylam
or Isis (as applicable), their respective Affiliates and sublicensees (but
with respect to Alnylam does not include Naked Sublicensees) to a Third
Party less the following items: (i) trade discounts, credits or
allowances, (ii) credits or allowances additionally granted upon returns,
rejections or recalls, (iii) freight, shipping and insurance charges, (iv)
taxes, duties or other governmental tariffs (other than
34
income taxes) and (v) government-mandated rebates and (vi) a reasonable
reserve for bad debts. Except in the cases of Products used to conduct
clinical trials, reasonable amounts of Products used as marketing samples
and Product provided without charge for compassionate or similar uses, a
Party, its Affiliates or sublicensees will be treated as having sold
Products for an amount equal to the fair market value of Products if: (a)
Products are used by such Party, its Affiliates or sublicensees without
charge or provision of invoice, or (b) Products are provided to a Third
Party by such Party, its Affiliates or sublicensees without charge or
provision of invoice and used by such third party.
In the event the Product is sold as part of a Combination Product (as
defined below), the Net Sales from the Combination Product, for the
purposes of determining royalty payments, shall be determined by
multiplying the Net Sales (as determined without reference to this
paragraph) of the Combination Product, during the applicable royalty
reporting period, by the fraction, A/A+B, where A is the average sale
price of the Product when sold separately in finished form and B is the
average sale price of the other product(s) included in the Combination
Product when sold separately in finished form, in each case during the
applicable royalty reporting period or, if sales of both the Product and
the other product(s) did not occur in such period, then in the most recent
royalty reporting period in which sales of both occurred. In the event
that such average sale price cannot be determined for both the Product and
all other products(s) included in the Combination Product, Net Sales for
the purposes of determining royalty payments shall be calculated by
multiplying the Net Sales of the Combination Product by the fraction of
C/C+D where C is the fair market value of the Product and D is the fair
market value of all other product(s) included in the Combination Product.
As used above, the term "Combination Product" means any pharmaceutical
product which consists of a Product and other therapeutically active
pharmaceutical compound or any delivery technology that embodies
substantial intellectual property rights Controlled by the selling Party
(e.g., a common syringe would not constitute a delivery technology that
embodies substantial intellectual property rights Controlled by the
selling Party, but an implantable delivery device such as a stent would
constitute such a delivery technology).
52. "Patent" or "Patents" means (a) patent applications (including provisional
applications and applications for certificates of invention); (b) any
patents issuing from such patent applications (including certificates of
invention); (c) all patents and patent applications based on,
corresponding to, or claiming the priority date(s) of any of the
foregoing; (d) any substitutions, extensions (including supplemental
protection certificates), registrations, confirmations, reissues,
divisionals, continuations, continuations-in-part, re-examinations,
renewals and foreign counterparts thereof; and (e) all patents claiming
overlapping priority therefrom.
53. "Person" means any person, organization, corporation or other business
entity.
54. "Product" means either an Alnylam Product or an Isis Product as the case
may be.
55. "Regulatory Authority" means any applicable government regulatory
authority involved in granting approvals for the marketing and/or pricing
of a Product
35
worldwide including, without limitation, the United States Food and Drug
Administration ("FDA") and any successor government authority having
substantially the same function, and foreign equivalents thereof.
56. "Research Use" means discovering, developing and optimizing an Alnylam
Product or an Isis Product, as applicable, up to, but not including, [**],
and/or conducting pilot manufacturing studies of an Alnylam Product or an
Isis Product, as applicable. Research Use may include small pilot
toxicology studies. With respect to Isis, Research Use does not include
studies [**] for potential drug targets, but does include studies [**] for
development of Double Stranded RNA Products from among potential targets
for which a reasonable scientific basis exists for believing that such
potential targets are associated with a particular disease or condition.
57. "Reserved Target" has the meaning set forth in Section 6.4(a).
58. "Series D Preferred Stock" means Series D Convertible Preferred Stock of
Alnylam as further defined in the Equity Documents.
59. "Sublicense Revenue" means any payments that Alnylam receives from a
sublicensee in consideration of a Naked Sublicense, including, but not
limited to, license fees, royalties, milestone payments, and license
maintenance fees, but excluding: (i) payments made in consideration of
equity or debt securities of Alnylam at fair market value and (ii)
payments specifically committed to reimburse Alnylam for the
fully-burdened cost of research and development. If Alnylam receives any
non-cash Sublicense Revenue, Alnylam will pay Isis, at Isis' election,
either (x) a cash payment equal to the fair market value of Isis'
appropriate portion of the Sublicense Revenue or (y) the in-kind portion,
if practicable, of the Sublicense Revenue.
60. "Technology Access Fee" means any payments that Alnylam receives from
granting a Third Party access (through sublicense or otherwise) to the
Isis Patent Rights as part of a Bona Fide Collaboration or Development
Collaboration agreement, including, but not limited to, license fees,
collaboration fees, option fees, payments made in consideration for the
issuance of equity or debt securities above fair market value, payments
made for research and development support above Alnylam's fully-burdened
cost, but excluding the following payments: (i) payments made in
consideration for equity or debt securities of Alnylam at fair market
value, (ii) payments made in consideration for thirty-five percent (35%)
or more of Alnylam's equity securities at fair market value plus a
reasonable control premium, (iii) payments specifically committed to
reimburse Alnylam for the fully-burdened cost of research and development,
including without limitation the fully-burdened cost of products
transferred by Alnylam in connection with such research and development,
(iv) milestone payments, (v) payments associated with the sale of
commercial products, and (vi) payments that count as Sublicense Revenue
under a Naked Sublicense subject to Alnylam's payment obligations to Isis
under Section 7.4. If Alnylam receives any non-cash Technology Access
Fees, Alnylam will pay Isis, at Isis' election, either (x) a cash payment
equal to the fair market value of Isis' appropriate portion of the
Technology Access Fee or (y) the in-kind portion, if practicable, of the
Technology Access Fee.
61. "Third Party" means any party other than Isis or Alnylam and their
respective Affiliates.
62. "Valid Claim" means (i) an issued claim of an unexpired Patent that has
not been withdrawn, canceled or disclaimed, or held invalid or
unenforceable by a court of competent jurisdiction in an unappealed or
unappealable decision, or (ii) a claim
36
of a patent application which has been pending for less than [**] years
from the earliest priority date for such application.
37
EXHIBIT 6.5(D)
DESCRIPTION OF POTENTIAL PASS-THROUGH AMOUNTS PAYABLE TO STANFORD UNIVERSITY
The passages shown below are excerpted from the License Agreement between The
Board of Trustees of the Xxxxxx Xxxxxxxx Junior University ("Stanford") and
Alnylam Pharmaceuticals, Inc. dated September 17, 2003. These passages were
selected to provide Isis with sufficient information to understand its potential
obligation to Stanford pursuant to Section 6.5(d) of the Agreement.
DEFINITIONS
2.5 "Licensed Field of Use" means delivery of ex-vivo synthesized siRNA
Molecules for research, development and therapeutic uses (including a
diagnostic necessary for development, sale or reimbursement of a
therapeutic Licensed Product). The Licensed Field of Use specifically
excludes delivery of any system producing in vivo expressed siRNAs for
therapeutic use, including but not limited to episomal and integrated
vectors, and recombinant viruses.
2.7 "Co-Exclusive" means that, subject to Article 4, Stanford will only
grant one further license in the Licensed Territory in the Licensed Field
of Use.
GRANT
3.2 CO-EXCLUSIVITY. The license is Co-Exclusive, including the right to
sublicense pursuant to Article 13, in the Licensed Field of Use for a term
beginning on the Effective Date, and ending, on a country-by-country
basis, on the expiration of the last to expire of Licensed Patents.
3.4 EXCLUSIVITY.
(A) If the other Co-Licensee discontinues licensing this Field of Use,
then the Field of Use will become exclusive for Alnylam.
(B) If the other Co-Licensee discontinues any other therapeutic license
under the Licensed Patents, Stanford shall so inform Alnylam and
Alnylam shall have the option to obtain an exclusive, worldwide
sublicensable license to such therapeutic field. The terms of any
such license shall be negotiated in good faith by Stanford and
Alnylam. This option may be exercised by Alnylam by written notice
to Stanford at any time during a period of ninety (90) days after
notification by Stanford.
ROYALTIES
6.3 EARNED ROYALTY. In addition, Alnylam will pay Stanford earned royalties on
Net Sales as follows:
(A) [**]% of Net Sales for a Licensed Product subject to the following;.
38
(B) Such royalty payments shall be reduced up to [**]% (from [**]% of
Net Sales down to [**]% of Net Sales) by the amount of royalty paid
to access additional intellectual property necessary in order to
sell Licensed Products ("Additional Earned Royalties").
(C) Such royalty payments shall be reduced as follows:
(1) [**]% if Additional Earned Royalties are [**]% or less.
(2) [**]% if Additional Earned Royalties are greater than [**]%
but less than [**]%.
(3) [**]% if Additional Earned Royalties are equal to or greater
than [**]% but less than [**]%.
(4) [**]% if Additional Earned Royalties are equal to or greater
than [**]% but less than [**]%.
(5) [**]% if Additional Earned Royalties are equal to or higher
than [**]%.
(D) Only one royalty is due on each Licensed Product sold by Alnylam or
its sublicensees regardless of whether its manufacture, use,
importation or sale are or shall be covered by more than one patent
or patent application included in Licensed Patents under this
Agreement, and no further royalties will be due for use of such
Licensed Product by Alnylam or its sublicensee's customers.
6.4 CREDITABLE PAYMENTS. Creditable payments under this Agreement will be an
offset to Alnylam against each earned royalty payment which Alnylam would
be required to pay under Section 6.3 until the entire credit is exhausted.
6.5 MILESTONE PAYMENTS.
(A) For the first Licensed Product, Alnylam will make the following
payments for the filing of an IND initiation of Phase II trial,
initiation of Phase III trial, and approval of New Drug Application
or equivalent in the U.S. ("Milestone Payments"):
(1) $[**] for filing of first IND.
(2) $[**] for initiation of the First Phase II trial.
(3) $[**] for initiation of the First Phase III trial.
(4) $[**] for approval of the First New Drug Application or
equivalent regulatory approval in the U.S.
(B) For the second Licensed Product, Alnylam will make the following
Milestone Payments:
(1) $[**] for filing of first IND.
(2) $[**] for initiation of the First Phase II trial.
39
(3) $[**] for initiation of the First Phase III trial.
(4) $[**] for approval of the First New Drug Application or
equivalent regulatory approval in the U.S.
(C) For the third and every subsequent Licensed Product, Alnylam will
make the following Milestone Payments:
(1) $[**] for filing of first IND.
(2) $[**] for initiation of the First Phase II trial.
(3) $[**] for initiation of the First Phase III trial.
(4) $[**] for approval of the First New Drug Application or
equivalent regulatory approval in the U.S.
(D) Notwithstanding the above, at the time that Stanford receives a
Milestone Payment from Alnylam on behalf of a sublicensee under
13.6, the corresponding Milestone Payment under this Section 6.5
will not be due.
6.6 OBLIGATION TO PAY ROYALTIES. If this Agreement is not terminated in
accordance with other provisions, Alnylam will be obligated to pay
royalties on all Licensed Product that is either sold or produced under
the license granted in Article 3, whether or not the Licensed Product is
produced before the Effective Date of this Agreement or sold after the
Licensed Patent has expired.
13 SUBLICENSING
13.1 PERMITTED SUBLICENSING FOR LICENSED CO-EXCLUSIVE FIELD OF USE. Alnylam may
grant sublicenses in the Co-exclusive Licensed Field of Use during the
Co-Exclusive period:
(A) only in conjunction with intellectual property under Alnylam's
control; and
(B) only if Alnylam is developing or selling Licensed Products in the
Co-Exclusive Licensed Field of Use.
13.3 SUBLICENSE REQUIREMENTS. Any sublicense granted by Alnylam under this
Agreement will be subject and subordinate to terms and conditions of this
Agreement, except:
(A) Sublicense terms and conditions will reflect that any sublicensee
will not further sublicense, with the exception that sublicensee may
further sublicense rights under Licensed Patents only as needed or
implied in the course of distribution or performance of service as
required for the sale to an end user of Licensed Products; and
40
(B) The earned royalty rate specified in the sublicense may be at
different rates than the rates in this Agreement.
13.4 SUBLICENSES REVERT TO STANFORD. Any sublicense will expressly include the
provisions of Articles 7, 8, and 9 for the benefit of Stanford [Note:
these provisions are detailed in Exhibit 6.5(c)]. If a sublicensee desires
that its sublicense survive the termination of this agreement, Stanford
agrees that the sublicense will revert to Stanford subject to the transfer
of all obligations, including the payment of royalties specified in the
sublicense, to Stanford or its designee, if this Agreement is terminated.
13.5 COPY OF SUBLICENSES. Alnylam will provide Stanford in confidence a copy of
all relevant portions of any sublicenses granted pursuant to this Article
13.
13.6 SHARING OF SUBLICENSING INCOME. In addition to the earned royalties
defined in Article 6, Alnylam will pay Stanford [**] percent ([**]%) of
the amount received by Alnylam, that is specifically attributable to the
Licensed Patents, from a sublicensee in
(A) up-front license fees, and
(B) clinical Milestone Payments as defined in Article 6.5.
13.7 ROYALTY-FREE SUBLICENSES. Alnylam may grant royalty-free or noncash
sublicenses or cross-licenses if Alnylam pays all royalties due Stanford
from sublicensee's Net Sales.
41
EXHIBIT 8.2(C)
DESCRIPTION OF ALNYLAM ROYALTY OBLIGATIONS TO [**]EXISTING AS OF THE
EFFECTIVE DATE
As of the Effective Date, Alnylam has the following royalty obligations to [**]:
Alnylam is obligated to pay [**] running royalties on NET SALES (as defined in
Alnylam's agreements with [**]) of therapeutic and prophylactic LICENSED
PRODUCTS (as defined in Alnylam's agreements with [**]) by Alnylam and its
SUBLICENSEES (as defined in Alnylam's agreements with [**]) that range from
[**]% ([**] percent) to [**]% ([**] percent) of NET SALES, depending on the
level of NET SALES. Royalties payable by Alnylam to [**] are subject to the
following Royalty Stacking provision:
"5.3 Royalty Stacking
(a) Third Party Licenses
In the event COMPANY or a SUBLICENSEE takes, for objective commercial and/or
legal reasons, a license from any third party under any patent applications or
patents that dominate the PATENT RIGHTS or is dominated by the PATENT RIGHTS in
order to develop, make, use, sell or import any LICENSED PRODUCT (explicitly
excluding, without limitation, any third party patents and patent applications
for formulation, stabilization and delivery), then COMPANY is allowed to deduct
[**]% ([**] percent) of any additional running royalties to be paid to such
third party up to [**]% ([**] percent) of the running royalties stated in
Section 5.2, from the date COMPANY has to pay running royalties to such third
party. However, the running royalties stated in Section 5.2 shall not be reduced
to less than a minimum of [**]% ([**] percent) of NET SALES in any case.
For avoidance of doubt, if COMPANY or a SUBLICENSEE takes a license to a third
party target, COMPANY is in no event allowed to deduct any license fees for such
target from running royalties due to [**] under this Agreement."
Because Alnylam's right to reduce its royalty obligations to [**] pursuant to
the foregoing royalty stacking provision is not co-extensive with Isis' right to
reduce its royalty obligations to Alnylam pursuant to Section 8.2 of this
Agreement, Isis' right to reduce its royalty obligations to Alnylam pursuant to
Section 8.2 of this Agreement is limited, pursuant to Section 8.2(c) of this
Agreement, to the extent necessary to ensure that Isis' royalty obligations to
Alnylam are never less than Alnylam's royalty obligations to [**] with respect
to sales by Isis, its Affiliates and its sublicensees of any Isis Product.
42
ADDENDUM TRANSMITTAL
Reference is hereby made to the Strategic Collaboration and License
Agreement executed as of March 11, 2004 (the "Agreement"), between Isis
Pharmaceuticals, Inc., a Delaware corporation, and Alnylam Pharmaceuticals,
Inc., a Delaware corporation.
Capitalized terms used herein and not defined herein shall have the
meanings ascribed to them in the Agreement.
The Parties hereby acknowledge and agree that this document constitutes
the Addendum Transmittal.
Attached hereto are the following Exhibits and Schedules:
Exhibit 3.1
Exhibit 5.3(c)
Exhibit 5.3(d)
Exhibit 6.5(c)
Schedule 1-4
Schedule 1-5
Schedule 1-6
Schedule 1-27
Schedule 1-28
Schedule 1-30
Schedule 1-34
IN WITNESS WHEREOF, the Parties have executed this Addendum Transmittal as
of this 19th day of March, 2004.
ISIS PHARMACEUTICALS, INC. ALNYLAM PHARMACEUTICALS, INC.
By: /s/ B. Xxxxx Xxxxxxxx By: /s/ Xxxxxxx X. Xxxxx
------------------------------------ --------------------------------
Name: B. Xxxxx Xxxxxxxx Name: Xxxxxxx X. Xxxxx
---------------------------------- ------------------------------
Title: Executive Vice President Title: Senior Vice President,
--------------------------------- -----------------------------
Business Development
-----------------------------
SCHEDULE 1-4
ALNYLAM CURRENT CHEMISTRY PATENTS
Alnylam Current Chemistry Patents include all claims of the patents and patent
applications listed below that do not claim inhibitors to specific genes or gene
families.
Case No. Filing Date Country Serial No. Status Title
-------- ----------- ------- ---------- ------ -----
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
SCHEDULE 1-5
ALNYLAM CURRENT MOTIF AND MECHANISM PATENTS
Alnylam Current Motif and Mechanism Patents include all claims of the patents
and patent applications listed below that do not claim inhibitors to specific
genes or gene families.
Case No. Filing Date Country Serial No. Status Title
-------- ----------- ------- ---------- ------ -----
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**]
[**] [**] [**]
[**] [**] [**]
[**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**]+ Note that Alnylam's license to this series of patent applications
specifically excludes claims [**] and the equivalent claims in any patent
applications and patents
resulting from this PCT application. The application contains claims relating
to [**]. The claims excluded from Alnylam's license are those that [**].
* Subject to the provisions of section 6.5(d).
SCHEDULE 1-6
ALNYLAM EXCLUDED TECHNOLOGY
1. All Patent rights licensed to Alnylam under the license agreements
between [**] dated [**], and between [**] and Alnylam dated [**].
2. All Patent rights licensed to Alnylam under the license agreement
between [**] and Alnylam dated [**].
3. All Patent rights licensed to Alnylam under the license agreement
between [**] and Alnylam dated [**].
EXHIBIT 6.5(c)
RESTRICTIONS IMPOSED BY AGREEMENTS BETWEEN ALNYLAM AND THIRD PARTIES EXECUTED
PRIOR TO THE EFFECTIVE DATE
Because of agreements in effect with Third Parties as of the Effective Date, the
following restrictions and other terms apply to Alnylam Patent Rights with
respect to which Isis is granted a license, or option to obtain a license, under
this Agreement.
RIGHTS LICENSED FROM [**]
The rights licensed from [**] ("**") relate to the "[**]" and "[**]" patents.
"[**] patent" means the pending patent applications listed in Schedule 1-5 with
the following case numbers: [**].
"[**] patent" means the pending patent applications listed in Schedule 1-5 with
the following case numbers, excluding claims [**] (case number [**]) and the
equivalent claims in any patent applications and patents resulting from this PCT
application: [**].
The restrictions on, and other terms relating to, the rights available to Isis
under the Agreement are described in the following clauses excerpted from the
Co-Exclusive License executed between Alnylam and [**] on [**].
"ARTICLE 2 - GRANT OF RIGHTS
2.4 Sublicenses
.... Immediately after the signature of each sublicense granted under this
Agreement, COMPANY shall provide [**] with a copy of the signed sublicense
agreement, and COMPANY shall confirm in writing to [**] that COMPANY shall
be liable for payment of royalties on NET SALES of the SUBLICENSEE in
accordance with Sections 5.2 and 5.3.
ARTICLE 4 - COMPANY DILIGENCE OBLIGATIONS AND REPORTS
4.1 Activity Requirements
COMPANY shall use commercially reasonable efforts, and shall oblige its
SUBLICENSEES to use commercially reasonable efforts, to develop and to
introduce into the commercial market LICENSED PRODUCTS at the earliest
practical date.
4.2 Development Reports
Commencing with the beginning of 2003, COMPANY shall furnish, and shall
oblige its SUBLICENSEES to furnish to COMPANY for inclusion in its reports
to [**], to [**] in writing, within 30 (thirty) days after the end of each
calendar quarter with COMPANY's standard R&D report, as provided to the
investors
pursuant to the Amended and Restated Investor's Rights Agreement Series B,
on the progress of its efforts during the immediately preceding calendar
quarter to develop and commercialize LICENSED PRODUCTS for each indication
and sub-indication within the FIELD. The report shall also contain a
discussion of intended R&D efforts for the calendar quarter in which the
report is submitted.
4.4 Liability for SUBLICENSEES
If SUBLICENSEES of COMPANY develop, manufacture, use and/or sell LICENSED
PRODUCTS under the PATENT RIGHTS, COMPANY warrants and is liable towards
[**] that the SUBLICENSEES perform their sublicense agreement in
accordance with this Agreement, and COMPANY shall be responsible and
liable for royalty payments and reports of the SUBLICENSEES.
4.5 Effect of Failure
In the event that [**] determines that COMPANY or any of its SUBLICENSEES
has failed to fulfill any of its obligations under this Section 4, then
[**] may treat such failure as a material breach in accordance with
Section 11.7.
ARTICLE 5 - SHARES, Royalties and Payment Terms
5.2 Running Royalties
COMPANY shall pay to [**] the following running royalties on NET SALES of
therapeutic and prophylactic LICENSED PRODUCTS by COMPANY and its
SUBLICENSEES:
[[**]% ([**] percent) to [**]% ([**]%) of NET SALES depending on
level of NET SALES].
In the event that COMPANY or a SUBLICENSEE develops [**] LICENSED
PRODUCTS, COMPANY shall initiate negotiations with [**] at least 3 (three)
months prior to the intended first commercial sale of each [**]
LICENSED PRODUCT. COMPANY and [**] shall negotiate in good faith royalties
on reasonable market terms for such [**] LICENSED PRODUCT.
.... Non-cash consideration shall not be accepted by COMPANY or any
SUBLICENSEE for LICENSED PRODUCTS without the prior written consent
of [**].
5.3 Royalty Stacking
(a) Third Party Licenses
In the event COMPANY or a SUBLICENSEE takes, for objective commercial
and/or legal reasons, a license from any third party under any patent
applications or patents that dominate the PATENT RIGHTS or is dominated by
the PATENT RIGHTS in order to develop, make, use, sell or import any
LICENSED PRODUCT [**], then COMPANY is allowed to deduct [**]% ([**]
percent) of
any additional running royalties to be paid to such third party up to
[**]% ([**] percent) of the running royalties stated in Section 5.2, from
the date COMPANY has to pay running royalties to such third party.
However, the running royalties stated in Section 5.2 shall not be reduced
to less than a minimum of [**]% ([**] percent) of NET SALES in any case.
For avoidance of doubt, if COMPANY or a SUBLICENSEE takes a license [**],
COMPANY is in no event allowed to deduct any license fees [**] from
running royalties due to [**] under this Agreement.
(b) PATENT RIGHTS Coverage
In the event that (i) COMPANY or its SUBLICENSEES sell a LICENSED PRODUCT
in a country where no PATENT RIGHTS are issued and no patent applications
that are part of the PATENT RIGHTS are pending that have not been pending
for less than [**] years after filing national patent applications in the
country in question, and (ii) such LICENSED PRODUCT is manufactured in a
country where PATENT RIGHTS are issued or patent applications that are
part of the PATENT RIGHTS are pending that have not been pending for more
than [**] years after filing national patent applications in the country
in question, the royalties stated in Section 5.2 will be reduced by [**]%
([**] percent) for such LICENSED PRODUCT, until the expiration or
abandonment of all issued patents and filed patent applications within the
PATENT RIGHTS in the country in which the LICENSED PRODUCT is
manufactured.
5.4 Reports
Within 30 (thirty) days of the end of each calendar half year, COMPANY
shall deliver a detailed report to [**] for the immediately preceding
calendar half year showing at least (i) the number of LICENSED PRODUCTS
sold by COMPANY and its SUBLICENSEES in each country, (ii) the gross price
charged by COMPANY and its SUBLICENSEES for each LICENSED PRODUCTS in each
country, (iii) the calculation of NET SALES, and (iv) the resulting
running royalties due to [**] according to those figures. If no running
royalties are due to [**], the report shall so state.
5.6 Bookkeeping and Auditing
COMPANY is obliged to keep, and shall oblige its SUBLICENSEES to keep,
complete and accurate books on any reports and payments due to [**] under
this Agreement, which books shall contain sufficient information to permit
[**] to confirm the accuracy of any reports and payments made to [**].
[**], or [**] appointed agents, is authorized to check the books of
COMPANY, and, upon [**] request, COMPANY, or agents appointed by [**] for
COMPANY, shall check the books of its SUBLICENSEES for [**], [**]. The
charges for such a check shall be borne by [**]. In the event that such
check reveals an underpayment in excess of 5% (five percent), COMPANY
shall bear the full cost of such check and shall remit any amounts due to
[**] within thirty days of receiving notice thereof from [**].
The right of auditing by [**] under this Section shall expire five years
after each report or payment has been made. Sublicenses granted by COMPANY
shall provide that COMPANY shall have the right to check the books of its
SUBLICENSEES according to this Section 5.6.
5.7 No Refund
All payments made by COMPANY or its SUBLICENSEES under this [**] Agreement
are nonrefundable and noncreditable against each other.
ARTICLE 6 - Patent Prosecution AND Infringement
6.3 Infringement
COMPANY shall inform [**] promptly in writing of any alleged infringement
of the PATENT RIGHTS by a third party and of any available evidence
thereof.
Subject to COMPANY's right to join in the prosecution of infringements set
forth below, the OWNERS shall have the right, but not the obligation, to
prosecute in their own discretion and at their own expense, all
infringements of the PATENT RIGHTS. The total cost of any such sole
infringement action shall be borne by the OWNERS, and the OWNERS shall
keep any recovery or damages derived therefrom. In any such infringement
suits, COMPANY shall, at the OWNERS' expense, cooperate in all respects.
COMPANY shall have the right to join the OWNERS' prosecution of any
infringements of the PATENT RIGHTS: In any such joint infringement suits,
the OWNERS and COMPANY will cooperate in all respects. The OWNERS and
COMPANY will agree in good faith on the sharing of the total cost of any
such joint infringement action and the sharing of any recovery or damages
derived therefrom.
In the event that the OWNERS decide not to prosecute infringements of the
PATENT RIGHTS, neither solely nor jointly with COMPANY, GI shall offer to
COMPANY to prosecute any such infringement in its own discretion and at
its own expense. .... The OWNERS shall, at COMPANY'S expense, cooperate.
The total cost of any such sole infringement action shall be borne by
COMPANY, and COMPANY shall keep any recovery or damages derived therefrom.
In the event that COMPANY intends to make any arrangements with the
infringer to settle the infringement (such as sublicenses), and solely the
OWNERS or the OWNERS jointly with COMPANY have prosecuted the
infringement, any such settlement needs the prior written approval of GI,
which shall not unreasonably be withheld; reasons to withheld include,
without limitation, that the settlement is financially disadvantageous for
the OWNERS or [**]. Any infringer to which COMPANY grants such sublicenses
shall be a SUBLICENSEE under this Agreement.
ARTICLE 8 - CONFIDENTIALITY
8.2 Obligation for [**]
The content of this Agreement and any information marked confidential
which is disclosed to [**] under this Agreement by COMPANY or its
SUBLICENSEES shall be treated confidential by [**] during the TERM and for
[**] years thereafter. [**] shall not use such information for any
purposes other than those necessary to directly further the purpose of
this Agreement. [**] may disclose such information to the OWNERS, provided
however, that the OWNERS are obliged to confidentiality to the same extent
as [**].
The confidentiality obligation shall not apply to information which is (i)
publicly available or becomes publicly available through no fault of [**],
or (ii) obtained by [**] from another source without a duty of
confidentiality, or (iii) demonstrably independently developed or
possessed by [**], or (iv) is required by law, regulation, accounting
principles or an order of a court or government agency to be disclosed.
ARTICLE 10 - General Compliance with Laws
10.2 Non-Use of OWNERS Names
Neither COMPANY nor its SUBLICENSEES shall use the name of [**] or any
variation, adaptation, or abbreviation thereof, or of any of its trustees,
officers, faculty, students, employees, or agents, or any trademark owned
by any of the OWNERS, in any promotional material or other public
announcement or disclosure without the prior written consent of the OWNERS
or in the case of an individual, the consent of that individual. The
foregoing notwithstanding, without the consent of the OWNERS, COMPANY may
state generally that it is co-exclusively licensed by the OWNERS under the
PATENT RIGHTS.
ARTICLE 11 - EFFECTIVENESS AND TERMINATION
11.5 Attack on PATENT RIGHTS
[**] shall have the right to terminate this Agreement immediately upon
written notice to COMPANY, if COMPANY attacks, or has attacked or supports
an attack through a third party, the validity of any of the PATENT RIGHTS.
To the extent legally enforcable, sublicenses granted by COMPANY shall
provide that in the event the SUBLICENSEE attacks, or has attacked or
supports an attack through a third party, the validity of any of the
PATENT RIGHTS, COMPANY shall have the right to terminate the sublicense
agreement immediately; upon request of [**], COMPANY shall have the
obligation to terminate such sublicense agreement.
11.8 Effect of Termination
.... In no event shall termination of this Agreement release COMPANY or
its SUBLICENSEES from the obligation to pay any amounts that became due on
or before the effective date of termination.
In the event that any license granted to COMPANY under this Agreement is
terminated, any sublicense under such license granted prior to termination
of said license shall remain in full fore and effect, provided that:
(a) the SUBLICENSEE is not then in breach of its sublicense agreement, and
(b) the SUBLICENSEE agrees to be bound to [**] as licensor under the terms
and conditions of the sublicense agreement, provided that [**] shall have
no other obligation than to leave the sublicense granted by COMPANY in
place."
RIGHTS LICENSED FROM [**]
The rights licensed from [**] ("[**]") relate to the pending patent applications
listed in Schedule 1-5 with the following case numbers: [**].
The restrictions on, and other terms relating to, the rights available to Isis
under the Agreement are described in the following clauses excerpted from the
agreement executed between Alnylam and [**] on [**]. Articles 7, 8 and 9 of such
agreement are included in these excerpts because clause 13.4 of such agreement
states that "Any sublicense will expressly include the provisions of Articles 7,
8, and 9 for the benefit of [**]."
"7 ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING
7.1 QUARTERLY EARNED ROYALTY PAYMENT AND REPORT. Beginning with the first
sale of a Licensed Product, Alnylam will make written reports (even if
there are no sales) and earned royalty payments to [**] within thirty days
after the end of each calendar quarter. This report will be in the form of
the report of Appendix B and will state the number, description, and
aggregate Net Sales of Licensed Product during the completed calendar
quarter, and resulting calculation pursuant to Section 6.3 of earned
royalty payment due [**] for the completed calendar quarter. With each
report, Alnylam will include payment due [**] of royalties for the
completed calendar quarter."
7.2 TERMINATION REPORT. Alnylam will make a written report to [**] within
ninety days after the license expires under Section 3.2. Alnylam will
continue to make reports after the license has expired, until all Licensed
Product produced under the license have been sold or destroyed. Concurrent
with the submittal of each post-termination report, Alnylam will pay [**]
all applicable royalties.
7.3 ACCOUNTING. Alnylam will keep and maintain records for a period of
three years showing the manufacture, sale, use, and other disposition of
products sold or otherwise disposed of under the license. Records will
include general-ledger records showing cash receipts and expenses, and
records that include production records, customers, serial numbers, and
related information in sufficient detail to enable Alnylam to determine
the royalties payable under this Agreement.
7.4 AUDIT BY [**]. Alnylam will permit an independent certified public
accountant selected by [**] and acceptable to Alnylam to examine Alnylam's
books and records from time to time (but no more than one time a year) to
the extent necessary to verify reports provided for in Sections 7.1 and
7.2. [**] will pay for the cost of such audit, unless the results of the
audit reveal an underreporting of royalties due [**] of five percent or
more, in which case, Alnylam will pay the audit costs.
8 NEGATION OF WARRANTIES
8.1 To the best of [**] OTL knowledge, [**] is the sole owner of Licensed
Patent and has the right to enter into this Agreement and to grant the
rights and licenses set forth herein.
8.2 NEGATION OF WARRANTIES. Nothing in this Agreement is construed as:
(A) [**] warranty or representation as to the validity or scope of
any Licensed Patent;
(B) A warranty or representation that anything made, used, sold,
or otherwise disposed of under any license granted in this
Agreement is or will be free from infringement of patents,
copyrights, and other rights of third parties;
(C) An obligation to bring suit against third parties for
infringement, except as described in Article 12;
(D) Granting by implication, estoppel, or otherwise any licenses
or rights under patents or other rights of [**] or other
persons other than Licensed Patent, regardless of whether the
patents or other rights are dominant or subordinate to any
Licensed Patent; or
(E) An obligation to furnish any technology or technological
information.
8.3 NO WARRANTIES. Except as expressly set forth in this Agreement, [**]
makes no representations and extends no warranties of any kind, either
express or implied. There are no express or implied warranties of
merchantability or fitness for a particular purpose, or that Licensed
Product will not infringe any patent, copyright, trademark, or other
rights, or any other express or implied warranties.
8.4 SPECIFIC EXCLUSION. Nothing in this Agreement grants Alnylam any
express or implied license or right under or to [**] entitled [**] or any
patent application corresponding thereto.
9 INDEMNITY
9.1 INDEMNIFICATION. Alnylam will indemnify, hold harmless, and defend
[**] and [**] Hospitals and Clinics, and their respective trustees,
officers, employees, students, and agents against all claims for death,
illness, personal injury, property damage, and improper business practices
arising out of the manufacture, use, sale, or other disposition of
Invention, Licensed Patent, Licensed Product, by Alnylam or any
sublicensee, or their customers except to the extent such claims are due
to the gross negligence or willful misconduct of [**]. [**] agreed to
promptly notify Alnylam in writing of any such claim and Alnylam shall
manage and control, at its own expense, the defense of such claim and its
settlement. Alnylam agrees not to settle any such claim against [**]
without [**] written consent where such settlement would include any
admission of liability on the part of [**], where the settlement would
impose any restriction on the conduct by [**] of any of its activities, or
where the settlement would not include an unconditional release of [**]
from all liability for claims that are the subject matter of such claim.
9.2 NO LIABILITY. Subject to Section 9.1, neither party will be liable to
each other for any loss profit, expectation, punitive or other indirect,
special, consequential, or other damages whatsoever, in connection with
any claim arising out of or related to this Agreement whether grounded in
tort (including negligence), strict liability, contract, or otherwise.
9.3 WORKERS' COMPENSATION. Alnylam will at all times comply, through
insurance or self-insurance, with all statutory workers' compensation and
employers' liability requirements covering all employees with respect to
activities performed under this Agreement.
9.4 INSURANCE. Alnylam will maintain, during the term of this Agreement,
Comprehensive General Liability Insurance, including Product Liability
Insurance prior to commercialization, with a reputable and financially
secure insurance carrier to cover the activities of Alnylam and its
sublicensees. Upon initiation of human clinical trials of Licensed
Product, such insurance will provide minimum limits of liability of Five
Million Dollars and will include [**] and [**] Hospitals and Clinics, and
their respective trustees, directors, officers, employees, students, and
agents as additional insureds. Insurance will be written to cover claims
incurred, discovered, manifested, or made during or after the expiration
of this Agreement and must be placed with carriers with ratings of at
least A- as rated by A.M. Best. Alnylam will furnish a Certificate of
Insurance evidencing primary coverage and additional insured requirements
and requiring thirty (30) days prior written notice of cancellation or
material change to [**]. Alnylam will advise [**], in writing, that it
maintains excess liability coverage (following form) over primary
insurance for at least the minimum limits set forth above. All insurance
of Alnylam will be primary coverage; insurance of [**] and [**] Hospitals
and Clinics will be excess and noncontributory.
12 INFRINGEMENT BY OTHERS: PROTECTION OF PATENTS
12.1 INFRINGEMENT ACTION.
(A) The parties will promptly inform each other of any suspected
infringement of any Licensed Patent by a third party.
(B) [**], Licensee and the other Co-Exclusive licensee will
meet to discuss the matter during the Co-Exclusive period of
this Agreement.
(C) If the Field-of-Use becomes Exclusive for Licensee, [**]
and Licensee will meet to discuss the matter during the
Exclusive period of this Agreement.
(D) If [**] does not choose to institute suit against said
third party within sixty days of notification, then the suit
may be brought in both Licensee's and the other Co-Exclusive
licensee's names, and [**] name if necessary and the
out-of-pocket costs thereof shall be borne equally by Licensee
and the other Co-Exclusive licensee and any recovery or
settlement shall be shared equally between Licensee and the
other Co-Exclusive licensee. In such situation, Licensee and
the other Co-Exclusive licensee shall agree to the manner in
which they exercise control over such action and if either
party desires to also be represented by separate counsel of
its own selection, the fees for such counsel shall be paid by
such party.
(E) If both [**] and the other Co-Exclusive licensee, or
[**] if there is no other Co-Exclusive Licensee, choose
not to institute suit against said third party within sixty
days of notification, then Licensee shall have the right to
institute suit in its own name or if necessary, in [**]
name, to enjoin such infringement. Licensee shall bear the
entire cost of such litigation and shall be entitled to retain
the entire amount of any recovery or settlement. However, any
recovery in excess of litigation/settlement costs will be
considered Net Sales and Licensee will pay [**] royalties
as indicated in Article 6 hereof. [**] shall provide
reasonable assistance to Licensee in the prosecution of any
such suit brought by Licensee, at Licensee's expense.
13 SUBLICENSING
13.1 PERMITTED SUBLICENSING FOR LICENSED CO-EXCLUSIVE FIELD OF USE.
Alnylam may grant sublicenses in the Co-exclusive Licensed Field of
Use during the Co-Exclusive period:
(A) only in conjunction with intellectual property under
Alnylam's control; and
(B) only if Alnylam is developing or selling Licensed
Products in the Co-Exclusive Licensed Field of Use.
13.2 REQUIRED SUBLICENSING FOR LICENSED CO-EXCLUSIVE FIELD OF USE.
(A) If Alnylam or its sublicensee(s) is unable or unwilling
to serve or develop a potential market or market
territory for which there is a willing sublicensee,
Alnylam will, at [**] request, negotiate in good
faith a sublicense under the Licensed Patents, provided
that the same request has been made of the other
Co-Exclusive licensee.
(B) Bona fide business concerns of Alnylam will be
considered in any good faith negotiations for a
sublicense under this Agreement and Alnylam shall not be
required to license/sublicense any other intellectual
property to such sublicensee.
(C) If the other Co-Exclusive licensee itself or through its
sublicensees is already developing a product in the
market or market territory for which there is a willing
sublicensee, Alnylam will not be required to sublicense
to such party.
(D) In case that any other issue arises in the context of
Required Sublicensing, [**] will discuss and try to
resolve such issue with Alnylam in good faith.
13.3 SUBLICENSE REQUIREMENTS. Any sublicense granted by Alnylam under
this Agreement will be subject and subordinate to terms and
conditions of this Agreement, except:
(A) Sublicense terms and conditions will reflect that any
sublicensee will not further sublicense, with the
exception that sublicensee may further sublicense rights
under Licensed Patents only as needed or implied in the
course of distribution or performance of service as
required for the sale to an end user of Licensed
Products; and
(B) The earned royalty rate specified in the sublicense [**]
in this Agreement.
13.4 SUBLICENSES REVERT TO [**]. Any sublicense will expressly
include the provisions of Articles 7, 8, and 9 for the benefit of
[**]. If a sublicensee desires that its sublicense survive the
termination of this
agreement, [**] agrees that the sublicense will revert to
[**] subject to the transfer of all obligations, including the
payment of royalties specified in the sublicense, to [**] or its
designee, if this Agreement is terminated.
13.5 COPY OF SUBLICENSES. Alnylam will provide [**] in confidence a
copy of all relevant portions of any sublicenses granted pursuant to
this Article 13.
13.6 SHARING OF SUBLICENSING INCOME. In addition to the earned royalties
defined in Article 6, Alnylam will pay [**] [**] percent ([**]%)
of the amount received by Alnylam, that is specifically attributable
to the Licensed Patents, from a sublicensee in
(A) [**], and
(B) [**] as defined in [**].
13.7 ROYALTY-FREE SUBLICENSES. Alnylam may grant royalty-free or noncash
sublicenses or cross-licenses if Alnylam pays all royalties due
[**] from sublicensee's Net Sales."
EXHIBIT 5.3(D)
ISIS ENCUMBERED PATENT RIGHTS
The following schedule of encumbered Patents is provided by Isis
Pharmaceuticals, Inc. to Alnylam Pharmaceuticals, Inc., in connection with the
Strategic Collaboration and License Agreement between Alnylam and Isis (the
"AGREEMENT"). Capitalized terms used but not otherwise defined herein have the
meanings given to such terms in the Agreement.
This schedule and the information and disclosures contained in this
schedule are intended only to qualify and limit the licenses granted by Isis to
Alnylam in the Agreement and do not expand in any way the scope or effect of any
such licenses.
1. MERCK
The Patents identified by Isis docket numbers [**] cover the incorporation of
certain Merck-proprietary [**].
The licenses from Isis to Alnylam with respect to these Patents are limited to
the Isis Field. In addition, Merck has a research license to practice these
Patents in the Isis Field.
"Isis Field" means the use of [the Merck [**]] solely for the purposes of
developing [**].
Reference is made to the discussion regarding Merck nucleosides on the Excluded
Technology schedule.
2. GILEAD SCIENCES, INC.
Gilead has retained exclusive rights in the Patents identified by a "Gilead" in
the Third Party column to make, have made, use, import, export or sell compounds
and other subject matter claimed within the scope of the patents which are [**].
In addition, Gilead has a non-exclusive, non-sublicensable, non-assignable
license under such Patents to make and use CodeBlocker Compounds and
Oligonucleotide Delivery Systems for internal research purposes, but not for any
commercial purpose.
"Codeblocker Compound" means an oligonucleotide that binds directly to DNA or
RNA within a cell on a selective basis determined by the nucleotide sequence of
the target DNA or RNA and exerts its biological activity predominantly through
binding to DNA or RNA to inhibit the transcription or replication of the target
DNA or RNA or binding to RNA to inhibit the translation, processing, packaging
or regulatory activity of the target RNA. A Codeblocker Compound may also have a
mechanism of action or biological activity other than one conferred through
direct binding to RNA or DNA provided that (i) the compound originally was
designed to bind a target DNA or RNA and (ii) the final
compound or any compounds used to derive the final compound were not identified
using selective purification and polymerase amplification in any fashion. An
oligonucleotide, is [**]. An oligonucleotide includes RNA or DNA fragments, and
may be composed of naturally occurring or non-naturally occurring bases, sugars
or intersugar linkages. An oligonucleotide may have [**]. Oligonucleotides may
be made such that adjacent nucleoside or nucleoside fragments are linked
together by [**] linkages to form the [**] in the linkage.
"Oligonucleotide Delivery System" means any [**] which was developed by Gilead
on or prior to [**], and which (i) enhances the [**] of a Codeblocker Compound,
(ii) selectively delivers a Codeblocker compound to the intended [**], (iii)
provides [**], or (iv) otherwise favorably alters the [**] so as to enhance its
pharmacological activity of clinical value. "Oligonucleotide Delivery System"
includes [**].
Glaxo Xxxxx Xxxxx has retained rights (originally granted from Gilead to GSK) in
the Patents identified by a "Gilead" in the Third Party column to (i) conduct
research and development within the GSK Field and (ii) make, have made, use,
offer for sale, sell, supply and import within the GSK Field any form or dosage
of a GSK Codeblocker Compound and any GSK Codeblocker Delivery System used in
connection therewith.
GSK may grant sublicenses only (a) to affiliates, for any use within the GSK
Field, and (b) to non-affiliates only to the extent necessary to enable such
sublicensee to make, have made, use, offer for sale, sell, supply and import a
GSK Codeblocker Compound developed by GSK or a research or development
collaborator of GSK during the term of such collaboration and for which GSK
(alone or in conjunction with a commercialization partner for such compound) has
commenced or is prepared to commence human clinical trials.
"GSK Field" means research with respect to, and the development and use of, GSK
Codeblocker Compounds for the diagnosis, prevention or treatment of conditions
or diseases in humans.
"GSK Codeblocker Compound" means any material which (i) binds directly to DNA or
RNA within a cell on a selective basis determined by the nucleotide sequence of
the target DNA or RNA and exerts its biological activity predominantly through
binding to DNA or RNA to inhibit the transcription or replication of the target
DNA or RNA or binding to RNA to inhibit the translation, processing, packaging
or regulatory activity of the target RNA, and (ii) is a molecule [**], and (iii)
is not a naturally occurring protein that binds to DNA to regulate
transcription, or a peptide derived from such a naturally occurring protein, and
(iv) is [**], and (v) was not known by GSK prior to [**].
"GSK Codeblocker Delivery System" means any [**] which is developed by GSK or
Gilead pursuant to their Collaborative Research Agreement dated March 25, 1996,
and which (i) [**] a GSK Codeblocker Compound, (ii) [**] to the intended target
[**], (iii) provides [**] a GSK Codeblocker Compound from [**], or (iv)
otherwise [**] a GSK Codeblocker Compound so as to [**].
3. [**], INC.
Alnylam cannot grant Naked Sublicenses with respect to the Patents identified by
a "[**]" in the Third Party column or the Patents listed on Annex 3. In
addition, [**] has the first right to defend and enforce such Patents if it is
facing the greatest competitive threat from infringement.
Alnylam must notify Isis if it grants a sublicense of any kind to a Third Party
with respect to such Patents.
The [**] has the first right to defend and maintain the Patents with a docket
number containing "[**]."
Isis also has access to certain other [**] technology to the extent it is useful
for Antisense Products and Antisense Technology (both as defined in Annex 3).
However, in addition to the restrictions described above, this technology
carries certain other use restrictions depending on how the technology is
characterized under the in-license agreement. We do not believe that such
technology will be useful to Alnylam, but have provided a description of the
technology and its related encumbrances on Annex 3 attached hereto.
4. XXXXXX PATENTS.
The Patents identified by a "Xxxxxx" in the Third Party column can only be
sublicensed in combination with a product that (i) uses such Patents and (ii)
employs as a material element other Isis Patent Rights.
5. AMGEN, GSK, CHIRON AND PFIZER.
Amgen, Inc., Glaxo Xxxxx Xxxxx, Chiron Corporation and Pfizer, Inc. each have a
license to use some or all of the Patents identified by a "TV" in the Third
Party column for their own internal target validation research.
6. INTEGRATED DNA TECHNOLOGIES, INC.
With respect to the Patents identified by an "IDT" in the Third Party column,
Integrated DNA Technologies, Inc. has a nonexclusive license to make, have made,
use, import, offer to sell, sell and have sold oligonucleotides and other
related research products to the Academic Market.
"Academic Market" means end-users employed by and located at or in academic,
university, government, and other 501(c)(3) registered not-for-profit
organizations; provided however that specifically excluded from this definition
shall be those end-users at such institutions whose research is directly funded
by a for-profit corporation for the purpose of drug discovery, drug development,
or target validation/gene functionalization
wherein the funding corporation has a specific legal interest or right to the
data and information of the funded research
7. TRILINK BIOTECHNOLOGIES, INC.
TriLink Biotechnologies, Inc. has a non-exclusive license to the Patents
identified by a "TriLink" in the Third Party column to (i) make, use, distribute
and sell Licensed Products to purchasers who have signed a form license
agreement and (ii) have [**] in the manufacture of Licensed Products.
"Licensed Product" means [**]
- "Propyne" means any of the following [**]
[**]
ANNEX 3
If the Patents marked with either a B1 or B2 restriction are [**] prevails in
the [**] and [**] for such Patents broadly cover [**], the licenses under such
Patents are limited to discover, develop, make, have made, use, sell, have sold,
offer to sell, import and have imported Antisense Products and to practice
Antisense Technology; provided that the license will only extend to the issued
claims corresponding to the [**] and shall not extend to any other claim of such
Patents.
The licenses under the Patents marked with an F restriction are limited (i) to
discover, develop, make, have made, use, sell, have sold, offer to sell, import
and have imported Antisense Products which contain modifications which have
[**], (ii) to practice Antisense Technology using oligonucleotides [**] in such
oligonucleotides, and (iii) to discover, develop, make, have made, use, sell,
have sold, offer to sell, import and have imported Antisense Products which
target genes involved in [**].
The licenses under the Patents marked with a C or D restriction are limited to
discover, develop, make, have made, use, sell, have sold, offer to sell, import
and have imported Antisense Products and practice Antisense Technology, provided
that neither such Antisense Products nor such Antisense Technology use, or are
used with, [**].
The licenses under the Patents marked with an A restriction are limited to
discover, develop, make, have made, use, sell, have sold, offer to sell, import
and have imported Antisense Products and practice Antisense Technology, provided
that such Antisense Products and Antisense Technology use, or are used with, the
technology covered by the claims of such Patents solely for the [**] purposes
only.
The licenses under the Patents marked with an M restriction are limited to
discover, develop, make, have made, use, sell, have sold, offer to sell, import
and have imported Antisense Products and practice Antisense Technology, which
Antisense Products and Antisense Technology primarily act [**].
The licenses under the Patents marked with a K restriction are limited to
discover, develop, make, have made, use, sell, have sold, offer to sell, import
and have imported Antisense Products and practice Antisense Technology;
provided, however, that such licenses will not extend to [**].
For purposes of this description:
- Antisense Products means oligonucleotides or oligonucleotide analogs
or mimics thereof targeted to a specific sequence of RNA that
hybridize to such sequence and through such hybridization modulate
the production of the targeted gene product. The term Antisense
Products shall not include Ribozymes."
- Antisense Technology means the use of any oligonucleotide or
oligonucleotide analog or mimic thereof targeted to a specific
sequence of RNA that hybridizes to such sequence and through such
hybridization modulates the production of the targeted gene product.
The term Antisense Technology shall not include Ribozyme technology.
- Ribozymes means oligonucleotides or oligonucleotide analogs or
mimics containing a catalytic core having a bulge or stem loop and
regions flanking the catalytic core that hybridize to a targeted RNA
and modulate the targeted RNA by cleavage at a site next to a
specific ribonucleotide triplet by an oligonucleotide catalyzed
transesterification reaction.
- Ribozyme Technology means the use of any oligonucleotides or
oligonucleotide analogs or mimics thereof containing a catalytic
core having a bulge or stem loop and regions flanking the catalytic
core that hybridize to a targeted RNA and modulate the targeted RNA
by cleavage at a site next to a specific ribonucleotide triplet by
an oligonucleotide catalyzed transesterification reaction.
PATENT # HYBN # TITLE PATENT GROUP INVENTORS RESTRICTION
-------- ------ ----- ------------ --------- -----------
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**]
SCHEDULE 1-30
EXCLUDED TECHNOLOGY
The following schedule of Excluded Technology is provided by Isis
Pharmaceuticals, Inc. to Alnylam Pharmaceuticals, Inc., in connection with the
Strategic Collaboration and License Agreement between Alnylam and Isis (the
"AGREEMENT"). Capitalized terms used but not otherwise defined herein have the
meanings given to such terms in the Agreement.
This schedule and the information and disclosures contained in this
schedule are intended only to qualify and limit the licenses granted by Isis to
Alnylam in the Agreement and do not expand in any way the scope or effect of any
such licenses.
In the event of a conflict between this schedule of Excluded Technology
and any other schedule or terms of the Agreement, this schedule will govern.
1. INTELLECTUAL PROPERTY COVERING:
- RNA processing, including modulation of [**]
- PNA chemistry licensed or acquired from (i) [**];
- [**] chemistry licensed or acquired from [**];
- [**] a Gene Target.
2. [**]/4'-THIO CHEMISTRY.
4'-thio chemistries including patents licensed in from [**]
In addition, the following Patents in-licensed from the Centre National De
La Recherche Scientifique are excluded:
ISIS DOCKET PATENT GRANTED
NUMBER COUNTRY STATUS NUMBER DATE TITLE
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**]
3. GEN-PROBE AND NIH. (A)
The following Patents in-licensed from Gen-Probe Inc. and the National Institute
of Health are excluded:
U.S. Patent No. [**] entitled: [**];
U.S. Patent No. [**] entitled: [**]; and
U.S. Patent No. [**] entitled: [**]
4. XXXXXX UNIVERSITY (B)
In addition to certain manufacturing technology excluded by definition,
the following Patents in-licensed from XxXxxx University are excluded:
ISIS DOCKET
NUMBER COUNTRY STATUS TITLE
[**] [**] [**] [**]
[**] [**] [**] [**]
5. UNIVERSITY OF MASSACHUSETTS (B)
The following Patents in-licensed from the University of Massachusetts are
excluded:
[**] Patent No. [**] entitled [**];
[**] Patent Application [**] entitled "[**];
[**] Patent Application [**] entitled [**]; and
[**] Patent No. [**] entitled [**].
6. XXXXXX PATENTS (B)
The Xxxxxx Patents are excluded. "Xxxxxx Patents" means and includes [**].
Patent Nos. [**]; [**] Patent No. [**], and [**] Patent Application No. [**]
(allowed).
7. MERCK NUCLEOSIDE
Single nucleosides, nucleotides or monomers claimed in Patents filed as of the
Effective Date which are prosecuted by Merck and Co. are excluded. However if
such Patents are necessary for Alnylam to practice the licenses granted under
Section 5.1 with respect to a specific Alnylam Product, then Isis will include
such necessary Patents in the licenses granted under Section 5.1.
8. AJINOMOTO
Isis believes the agreement under which Isis received a license to the Ajinomoto
Patents listed below [**]. However, there is a dispute regarding [**].
ISIS DOCKET COUNTRY STATUS PATENT GRANT DATE TITLE
NUMBER NUMBER
[**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
[**] [**] [**] [**] [**] [**]
----------
(A) Isis cannot sublicense the technologies marked with this footnote.
(B) Although, Isis can sublicense the technologies marked with this footnote,
such a sublicense carries additional financial and other obligations. Isis
is willing to negotiate a separate sublicense agreement for these
technologies.
EXHIBIT 3.1
ISIS PHARMACEUTICALS
ALNYLAM PHARMACEUTICALS
CLINICAL SUPPLY AGREEMENT
MANUFACTURING SERVICES TERM SHEET
At Alnylam's request, Isis will provide Alnylam services in the categories
described below. Alnylam will compensate Isis for such services on a cost plus
[**]% basis.
1. For each drug candidate for which Alnylam wishes to engage Isis's
services, Isis and Alnylam will enter into a Manufacturing Agreement
pursuant to which Isis will [**] as may be mutually agreed by the parties.
2. Each year, in advance, Isis and Alnylam will detail a mutually agreed plan
of the services, if any, to be provided by Isis to Alnylam, including a
written estimate of the amount of API Alnylam will require for the drug
candidate during the subsequent calendar year.
3. Such plan will also detail manufacturing support services to be provided
by Isis in connection with the drug candidate, including process
development, analytical methods development and formulation services.
4. The Manufacturing Agreement will also specify which party will be
responsible for the Drug Master File for the drug candidate.
5. At the end of [**] or such other stage mutually agreed under paragraph (1)
above, the parties will agree either that Isis will continue to
manufacture the drug candidate or that Isis will transfer the
manufacturing process for such drug candidate to a third party
manufacturer designated by Alnylam on commercially reasonable license
terms.
SCHEDULE 1-27 ISIS CURRENT CHEMISTRY PATENTS
ISIS
DOCKET COUNTRY PATENT GRANT 3RD 3RD
NUMBER NAME STATUS NUMBER DATE ISISCASETYPE CURRENTOWNER ISISATTYAGENT TITLE PARTY PARTY
DELETED
SCHEDULE 1-28 ISIS CURRENT MOTIF AND MECHANISM PATENTS
ISIS DOCKET PATENT GRANT ISIS CURRENT ISIS 3RD 3RD
NUMBER COUNTRY STATUS NUMBER DATE CASE OWNER ATTY CODE COMMENTS TITLE PARTY PARTY
DELETED
SCHEDULE 1-34
ISIS MANUFACTURING PATENTS
The Parties have not yet agreed to a specific list of Manufacturing Patents as
of the date of the Addendum Transmittal. However, the Parties agree to work
together to develop a list of Manufacturing Patents by [**].
SCHEDULE 1-34
ISIS MANUFACTURING PATENTS
The Parties have not yet agreed to a specific list of Manufacturing Patents as
of the date of the Addendum Transmittal. However, the Parties agree to work
together to develop a list of Manufacturing Patents by [**].
